Professional Documents
Culture Documents
Hla Dictionary 2008
Hla Dictionary 2008
Hla Dictionary 2008
doi: 10.1111/j.1399-0039.2008.01183.x
The 2008 edition of the human leukocyte antigen (HLA) defined alleles can be used to identify potential donors listed
data dictionary is the fifth update; previous versions have in unrelated donor registry databases and umbilical cord
been published in 1997, 1999, 2001, and 2004 (1–4). The banks who have been typed by serology. Although the
HLA data dictionary is aimed at identifying the serological majority of laboratories use DNA-based methods for typing
types associated with each HLA-A, -B, -C, -DRB1, and today, there is a significant number of HLA assignments in
-DQB1 allelic product. The dictionary is a reference to help registries and banks that have been determined by serology-
with the identification of potential hematopoietic stem cell based methods. For example, in the database of almost 7
(HSC) donors. The serologic equivalents of the DNA- million volunteers of the National Marrow Donor Program
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170 95
HLA alleles and serologic types R. Holdsworth et al.
(NMDP) in the United States, the percent of serologic not expected to alter the antigenic expression. Nonex-
assignments for volunteer donors is still significant, with pressed alleles with unique four-digit designations are in-
45% of the HLA-A and -B loci, 31% of the -C locus, 4% of cluded for completeness. Nonexpressed alleles, which share
the -DRB1 locus, and 37% of the -DQB1 locus assignments a four-digit designation with an expressed allele (e.g.
defined serologically. The availability of serologic equiv- B*15010102N and B*15010101), have been excluded from
alents allows potentially matched volunteers typed by the tables.
serology to be matched to DNA-typed patients. The serologic assignment (third column of Tables 1–6) is
The number of newly identified HLA alleles grows each taken from the HLA Nomenclature report 2004 (6).
year and since the 2004 publication, 832 new HLA alleles Serologic specificities of newly identified alleles are only
have been added, including 235 HLA-A, 310 -B, 140 -C, 116 included when reported by the allele contributors as being
-DRB1, 9 -DRB3/4/5, and 22 -DQB1 alleles. Information identical or very similar to the standard specificity
has also been updated for 766 previously listed alleles associated with the allele group (e.g. A1 associated with
numbering 158 HLA-A, 303 -B, 116 -C, 133 -DRB1, 13 - A*01 alleles). Likewise, the contributor may report an allele
DRB3/4/5, and 43 -DQB1 alleles. This edition of the to be expressed as a serologically variant antigen. Such
dictionary includes all newly defined four-digit alleles information is included in the nomenclature report under
displayed in the IMGT/HLA database (5) to the end of the heading ‘previous equivalents’ and is included here in
July 2007 in Tables 1–6. the ‘Comments’ column of Tables 1–6. In some cases, the
Information for the 2008 edition of the dictionary has serological definition given in the WHO Nomenclature
been contributed from several sources. The World Health Report and displayed in the third column has been derived
Organization (WHO) serological assignment is taken from from the previous versions of the dictionary, as these data
the Nomenclature report 2004 (6) and from data submitted were considered sufficiently compelling to be adopted as the
to the WHO Nomenclature Committee for Factors of the WHO value. Such instances of dictionary-derived WHO
HLA System when a new allele is submitted for consider- values are indicated by a footnote in Tables 1–6.
ation. The International Cell Exchange, UCLA program
provides a unique opportunity to obtain the serologic type
of rare and unusual alleles. Updated information for 335 International Cell Exchange, UCLA
alleles was provided by the Cell Exchange for this dictionary The International Cell Exchange, UCLA provided data
edition. Results are routinely submitted from laboratories showing serologic equivalents for 49 HLA-A, 128 -B, 35 -C,
around the world. Half of the nearly 200 laboratories 88 -DRB1, 8 -DRB3, 3 -DRB4, 5 -DRB5, and 19 -DQB1
actively participating in the Cell Exchange are outside the alleles. The latest HLA class I analysis has been updated
United States, with laboratories in Canada, Europe, the with the inclusion of data from 136 new samples, cells 1185–
Middle East, Africa, Asia, Australia and New Zealand, 1320, from healthy individuals, characterized between
and South America. The serology typing data from this February 2004 and November 2007. Each cell was typed
program continue to enhance the dictionary information. by an average number of 100 laboratories, ranging from
The NMDP data for 454 alleles have been updated with a low of 83 to a high of 118. The parallel typing for HLA-A,
serologic typing information. The 13 IHWS data have been -B, and -C alleles using DNA-based methods was performed
taken from the 2004 edition of the data dictionary. There by an average of 46 laboratories, ranging from 43 to 51
have been no further updates on these data. The artificial reporting results for the monthly studies.
neural network (NN) analysis (7) has been rerun to provide The HLA class II analysis was updated with the typing
valuable data on the most likely serological result for information from 68 B lymphoblastoid cell lines (TER335-
a particular allele. The NN analysis now includes data for 402) from the same time period, February 2004 through
alleles of the HLA-C and -DQB1 loci. In addition, November 2007. Each cell was typed serologically by an
serological typing information has been submitted from average number of 13 laboratories, ranging from a low of 8
expert laboratories. The serology data from all sources have to a high of 18. The parallel typing for HLA-DRB1, -DRB3,
been summarized by the authors in the second column of -DRB4, -DRB5, and -DQB1alleles using DNA-based
Tables 1–6 as the expert assigned type. methods was performed by an average of 80 laboratories,
ranging from a low of 66 to a high of 87.
HLA serologic equivalents have been analyzed in
WHO nomenclature: allele and serologic heterozygous samples only if the other HLA allelic product
assignments would not interfere with the serologic recognition. The
The 2008 edition of the dictionary contains all alleles from associated serologic specificities as reported by the partici-
the IMGT/HLA database in release 2.18.0 July 2007. Only pating laboratories are given with the lowest and highest
the four-digit numbering of alleles is listed in the tables percentage recognition, shown in brackets in column 4 of
because the fifth and sixth digits (silent substitutions) are Tables 1–6.
96 ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 1 HLA-A alleles and their serologic designationsg
International Cell
Exchange, UCLA NMDP IHWS13 data NN
A*0101 A1 A1 A1 [98–100] 34a A1 [99] 5612 A1 113 The allele was used
for training of the
NN – A1
A*01010102N Not expressed Null – – – – – – NT
A*0102 A1 A1 – – A1 [95] 129 – – Training – A1
A*0103 A1 A1b A1 [99] 2 A1 [94]c 33 A1 5 Training – A1
cd
A*0104N Not expressed Null – – 1 – – NT
A*0106 A1 – – – A1 [100]c 3 – – A1
A*0107 A1 A1 – – – – – – A1
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
A*0108 A1 A1 – – – – – – A1 Normal A1
A*0109 A1 – – – – – – – A1
A*0110 A1 – – – – – – – A1
A*0111N Not expressed Null – – – – – – NT
A*0112 Undefined – – – – – – – Not assignede NN: A1
A*0113 A1 – – – – – – – A1
A*0114 A1 – – – – – – – A1
A*0115N Not expressed Null – – – – – – NT
A*0116N Not expressed Null – – – – – – NT
A*0117 A1 – – – – – – – A1
A*0118N Not expressed Null – – – – – – NT
A*0119 A1 A1 – – – – – – Not assignede NN: A1
A*0120 A1 – – – – – – – A1
A*0121 A1 – – – – – – – A1
A*0122N Not expressed Null – – – – – – NT
A*0123 A1 – – – – – – – A1
A*0124 A1 – – – – – – – A1
A*0125 A1 – – – – – – – A1
A*0126 A1 – – – – – – – A1
A*0127N Not expressed Null – – – – – – NT
A*0201 A2 A2 A2 [99–100] 117a A2 [98] 6315 A2 230 Training – A2
A*02010102L Low A2 Low A2 – – – – – – Identical to A*0201 Significantly reduced
or low cell surface
expression
A*0202 A2 A2 A2 [100]a 7 A2 [81] 859 A2 8 Training – A2 ihw13: variant
serum pattern
A*0203 A203/A2 A203 A2 [99–100]a 10 A2 [64] 472 A203 12 A2 ihw13: very short
A2
A*0204 A2 A2 – – A2 [77] 28 – – A2
HLA alleles and serologic types
97
Table 1 Continued
98
International Cell
Exchange, UCLA NMDP IHWS13 data NN
A*0208 A2 A2 – – A2 [100]c 7 – – A2
A*0209 A2 A2 – – A2 [100]c 10 – – A2
A*0210 A210/A2 A210 – – A2 [100]c 10 – – A2
A*0211 A2 A2 A2 [99] 1 A2 [74] 228 A2 17 A2 ihw13: short A2
A*0212 A2 A2 – – A2 [100]c 10 A2 1 A2
A*0213 A2 A2 – – A2 [100]c 17 – – A2
A*0214 A2 A2 – – A2 [100]c 7 – – A2
c
A*0215N Not expressed Null – – – – – NT
A*0216 A2 A2 – – A2 [81]c 16 – – A2
A*0217 A2 A2 – – A2 [73] 51 A2 2 A2
A*0218 A2 A2 – – A2 [100]c 1 – – A2
A*0219 A2 – – – Blank [100]c 1 – – A2
A*0220 A2 A2 – – A2 [100]c 26 – – A2 Normal A2
A*0221 A2 A2 – – – – – – A2
A*0222 A2 A2 – – A2 [100]c 21 – – A2
A*0224 A2 A2 – – A2 [100]c 11 – – A2
A*0225 A2 A2 – – – – – – A2
A*0226 A2 – – – A2 [100]c 3 – – A2
A*0227 A2 – – – A2 [100]c 1 – – A2
A*0228 A2 – – – A2 [100]c 1 – – A2
A*0229 A2 A2 – – A2 [100]c 2 – – A2
A*0230 A2 – – – A2 [100]c 7 – – A2
A*0231 A2 A2 – – – – – – A2
A*0232N Not expressed Null – – – – – – NT
A*0233 A2 – – – A2 [100]c 3 – – A2
A*0234 A2 A2 – – – – – – A2
A*0235 A2 A2 – – A2 [100]c 8 A2 2 A2 Normal A2
A*0236 A2 – – – A2 [100]c 1 – – A2 Normal A2
A*0237 A2 – – – – – – – A2
A*0238 A2 – – – A2 [67], blank [33]c 3 – – A2 Normal A2
A*0239 A2 – – – A2 [100]c 1 – – A2
A*0240 A2 – – – – – – – A2
A*0241 A2 A2 – – – – – – A2
A*0242 A2 A2 – – – – – – A2
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 1 Continued
International Cell
Exchange, UCLA NMDP IHWS13 data NN
HLA allele Expert assigned assigned Assigned type [%] tested type [%] tested Assignment tested type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
nine laboratories
performing serology
A*0250 A2 A2 – – – – – – A2
A*0251 A2 – – – – – – – A2
A*0252 A2 – – – – – – – A2
A*0253N Not expressed Null – – – – – – NT
A*0254 A2 – – – – – – – A2
A*0255 A2/A28 – – – – – – – Not assignede NN: A2, A28, A69
A*0256 A2 – – – – – – – A2 Short A2
A*0257 A2 – – – – – – – A2
A*0258 A2 – – – – – – – A2
A*0259 A2 A2 – – – – – – A2
A*0260 A2 – – – A2 [100]c 3 – – A2
A*0261 A2 – – – – – – – A2
A*0262 A2 – – – – – – – A2 A2 variant; A2x69
variant
A*0263 A2 – – – A2 [100]c 1 – – A2
cd
A*0264 A2 – – – 1 – – A2
A*0265 A2/A19 A2/19 – – – – – – Not assignede NN: A74
A*0266 A2 A2 – – A2 [100]c 2 – – A2
A*0267 A2 A2 – – – – – – A2
A*0268 A2 A2 – – – – – – A2
A*0269 A2 – – – – – – – A2
A*0270 A2 A2 – – – – – – A2
A*0271 A2 A2 – – – – – – A2
A*0272 A2 A2 – – – – – – A2
A*0273 A2 A2 – – – – – – A2
A*0274 A2 A2 – – – – – – A2
HLA alleles and serologic types
99
Table 1 Continued
100
International Cell
Exchange, UCLA NMDP IHWS13 data NN
A*0275 A2 – – – – – – – A2
A*0276 A2 – – – – – – – A2
A*0277 A2 A2 – – – – – – A2
HLA alleles and serologic types
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 1 Continued
International Cell
Exchange, UCLA NMDP IHWS13 data NN
HLA allele Expert assigned assigned Assigned type [%] tested type [%] tested Assignment tested type >0.55 Comments
A*9214 A2 – – – – – – – A2
A*9215 A2 – – – – – – – A2
A*9216 A2 – – – – – – – A2
A*9217 A2 – – – – – – – A2
A*9218 A2 – – – – – – – A2
A*9219 A2 – – – – – – – A2
A*9220 A2 – – – – – – – A2
A*9221 A2 – – – – – – – A2
A*9222 A2 – – – – – – – A2
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
A*9223 A2 – – – – – – – A2
A*9224 A2 – – – – – – – A2
A*9225N Not expressed Null – – – – – – NT
A*9226 A2 – – – – – – – A2
A*0301 A3 A3 A3 [98–100]a 44 A3 [99] 3504 A3 106 Training – A3
A*03010102N Not expressed Null – – – – NT
A*0302 A3 A3 A3 [99–100] 2 A3 [78] 342 A3 3 Training – A3
A*0303N Not expressed Null – – – – – – NT
cd
A*0304 A3 A3 – – 1 – – A3
A*0305 A3/blank A3 – – Blank [100]c 5 Blank 1 A3 ihw13: only reactive
with some A3 1 11
and A3 1 19 1 34
sera; normal A3
A*0306 A3/blank – – – – – A3/blank 1 A3 ihw13: very short A3
A*0307 A3 – – – A3 [75]c 4 – – A3
A*0308 A3 – – – A3 [100]c 4 – – A3
cd
A*0309 A3 – – – 1 A3 1 A3
A*0310 A3/blank – – – – – – – A3 A3 sera negative, only
A3 1 30 1 31 1 33
monoclonal
antibodie positive
A*0311N Not expressed Null – – – – – – NT
A*0312 A3 – – – – – – – A3
A*0313 A3 – – – – – – – A3
A*0314 A3 – – – – – – – A3
A*0315 A3 – – – – – – – A3
A*0316 A3 – – – – – – – A3
A*0317 A3 – – – – – – – A3
HLA alleles and serologic types
101
Table 1 Continued
102
International Cell
Exchange, UCLA NMDP IHWS13 data NN
A*0318 Undefined – – – – – – – A1
A*0319 A3 – – – – – – – A3
A*0320 A3 A3 – – – – – – A3
HLA alleles and serologic types
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 1 Continued
International Cell
Exchange, UCLA NMDP IHWS13 data NN
HLA allele Expert assigned assigned Assigned type [%] tested type [%] tested Assignment tested type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
A*1132 A11 – – – – – – – A11
A*2301 A23 A23(9) A23 [95–100]a 29 A23 [95], A24 [1] 5119 A23 42 Training – A9, A23
A*2302 A23 – – – A23 [100]c 5 – – A23
A*2303 A23 – – – A9 [100]c 1 – – A23
A*2304 A23 A23(9)b – – – – A23 1 A23 ihw13: short A23,
negative with A9 1
80 (11) sera
A*2305 A23 – – – A23 [100]c 2 – – A23
A*2306 A23 – – – – – – – A23
A*2307N Not expressed Null – – – – – – NT
A*2308N Not expressed Null – – – – – – NT
A*2309 A23 – – – – – – – A23
A*2310 A23 – – – – – – – A23
A*2311N Not expressed Null – – – – – – NT
A*2312 A23 A23(9) – – – – – – A23
A*2313 A23 – – – – – – – A23
A*2314 A23 – – – – – – – A23
A*2315 A23 – – – – – – – A23
A*2316 A23 – – – – – – – A23
A*2402 A24 A24(9) A24 [97–100] 99a A24 [97], A2403 [1] 3098 A24 146 Training – A9, A24
A*24020102L Low A24 Low A24(9) A24 [0–5]a 3 – – Blank 1 Identical to A*2402 Significantly reduced
or low cell surface
expression
A*2403 A2403/A24 A2403 A24 [66–68], A2403 10 A24 [55], blank [20], 282 A24 5 A24 ihw13: short A24,
[29–31]a A9 [4], A2403 [1] negative with A9 1
80 (11) sera
A*2404 A24 A24(9) – – A24 [62], blank [25], 8 – – A9
A2403 [13]c
HLA alleles and serologic types
103
Table 1 Continued
104
International Cell
Exchange, UCLA NMDP IHWS13 data NN
A*2407 A24 A24(9) A24 [99–100]a 21 A24 [59] 320 A24 17 Training – A9, A24
A*2408 A24 A24(9) – – A24 [47], blank [26] 30 – – A24 Short A24, similar to
A2403
A*2409N Not expressed Null – – Blank [100]c 2 – – NT
A*2410 A2403/A24 A2403 – – A24 [42], A9 [9], blank 32 A24 1 A24 A2403; ihw13: short
[16], A2403 [3] A24
A*2411N Not expressed Null Blanka 1 Blank [100]c 2 – – NT
cd
A*2413 A24 A24(9) – – 1 – – A24
A*2414 A24 A24(9) – – A24 [82]c 11 – – A24
c
A*2415 A24 – – – – – – A24
A*2417 A24 A24(9)b – – A24 [82]c 11 A24 3 A24 ihw13: short A24
A*2418 A24/A3 A24(9)/A3 – – – – – – A9f A2403x3; short A24
with most A3 and
A9 reactive; NN:
A24
A*2419 A9 A9 – – – – – – A24 Very short A9
A*2420 A24 A24(9)b – – A24 [100]c 9 A24 1 A24
A*2421 A24/A9 A24(9) – – – – – – A24 A9variant; A24 sera
negative
A*2422 A24 A9 – – A24 [83]c 6 A24 1 A24 ihw13: short A24,
negative with A9 1
80 (11) sera; A2403
like
A*2423 A24 A2403 – – A24 [100]c 11 – – A24 A2403
A*2424 A9 – – – – – – – A9f NN: A23
A*2425 A24 – – – A24 [100]c 13 – – A24
A*2426 A24 – – – A24 [100]b 2 – – A24
A*2427 A24 A24(9)b – – – – A24 1 A24 ihw13: short A24
A*2428 A9 A24(9) – – A24 [50], A9 [50]c 2 – – Not assignede NN: A9, A24, A2
A*2429 A24 – – – A24 [100]c 1 – – A24
A*2430 A24 – – – – – – – A24
A*2431 A24 – – – – – – – A24
A*2432 A24 – – – A24 [100]c 4 – – A24
A*2433 A2403/A24 A2403 A24 [99–100]a 4 A24 [100]c 4 A24 1 A24 A2403
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 1 Continued
International Cell
Exchange, UCLA NMDP IHWS13 data NN
HLA allele Expert assigned assigned Assigned type [%] tested type [%] tested Assignment tested type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
A*2443 A24 A24(9) – – – – – – A24
A*2444 A9 – – – – – – – A9f NN: A24
A*2445N Not expressed Null – – – – – – NT
A*2446 A24 – – – – – – – A24
A*2447 A24 – – – – – – – A24
A*2448N Not expressed Null – – – – – – NT
A*2449 A24 – – – – – – – A24
A*2450 A24 – – – – – – – A24
A*2451 A24 – – – – – – – A24
A*2452 A24 – – – – – – – A24
A*2453 A24 – – – – – – – A24
A*2454 A24 – – – – – – – A24
A*2455 A24 – – – – – – – A24
A*2456 A24 – – – – – – – A24
A*2457 A24 – – – – – – – A24
A*2458 A24 A24(9) – – – – – – A24
A*2459 A24 – – – – – – – A24
A*2460N Not expressed Null – – – – – – NT
A*2461 A24 – – – – – – – A24
A*2462 A24 – – – – – – – A24
A*2463 A24 – – – – – – – A24
A*2464 A24 – – – – – – – A24
A*2465 A24 – – – – – – – A24
A*2466 A24 – – – – – – – A24
A*2467 A24 – – – – – – – A24
A*2468 A24 – – – – – – – A24
A*2469 A24 – – – – – – – A24
A*2470 A24 – – – – – – – A24
HLA alleles and serologic types
105
Table 1 Continued
106
International Cell
Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 1 Continued
International Cell
Exchange, UCLA NMDP IHWS13 data NN
HLA allele Expert assigned assigned Assigned type [%] tested type [%] tested Assignment tested type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
A*2625N Not expressed Null – – – – – – NT
A*2626 A26 A10 – – – – – – A26
A*2627 A26 – – – – – – – A26
A*2628 A26 – – – – – – – A26
A*2629 A26 A26(10) – – – – – – A26
A*2630 A26 – – – – – – – A26
A*2631 A26 – – – – – – – A26
A*2632 A26 – – – – – – – A26
A*2633 A26 – – – – – – – A26
A*2634 A26 – – – – – – – A26
A*2635 A26 – – – – – – – A26
A*2901 A29 A29(19) A29 [98]a 1 A29 [96] 115 A29 10 Training – A29
A*29010102N Not expressed Null – – – – – – NT
A*2902 A29 A29(19) A29 [98–100]a 17 A29 [99] 1488 A29 28 Training – A29
A*2903 A29 – – – A29 [100]c 4 – – A29
A*2904 A29 – – – A29 [100]c 1 – – A29
A*2905 A29 – – – – – – – A29
A*2906 A29 – – – – – – – A29
A*2907 A29 – – – – – – – A29
A*2908N Not expressed Null – – – – – – NT
A*2909 A29 – – – – – – – A29
A*2910 A29 A29(19) – – A29 [100]c 2 – – A29
A*2911 A29 – – – – – – – A29
A*2912 A29 – – – – – – – A29
A*2913 Undefined – – – – – – – Not assignede NN: A32, A29
A*2914 Undefined – – – – – – – Not assignede NN: A29, A30
A*2915 A29 – – – – – – – A29
A*2916 A29 A29(19) – – – – – – A29
HLA alleles and serologic types
107
Table 1 Continued
108
International Cell
Exchange, UCLA NMDP IHWS13 data NN
A19 [1]
A*3003 A30 A30(19) – – A30 [83], blank [17]c 6 – – A30
A*3004 A30 A30(19) A30 [97–98]a 2 A30 [94] 85 A30 7 Training – A30
cd
A*3006 A30 – – – 1 – – A30
A*3007 A30 – – – A30 [100]c 2 – – A30
A*3008 A30 – – – – – – – A30
A*3009 A30 – – – A30 [100]c 3 A30 1 A30 ihw13: very short
A30, only broad
A19 sera reactive
A*3010 A30 – – – A30 [100]c 10 – – A30
A*3011 A30 A30(19) – – – – – – A30
A*3012 A30 – – – – – – – A30
A*3013 A30 – – – – – – – A30
A*3014L A30 Low A30(19) – – – – – – A30 Significantly reduced
or low cell surface
expression
A*3015 A30 A30(19) – – – – – – A30
A*3016 A30 – – – – – – – A30
A*3017 A30 A30(19) – – – – – – A30
A*3018 A30 A30(19) – – – – – – A30
A*3019 A30 – – – – – – – A30
A*3020 A30 – – – – – – – A30
A*3021 A30 – – – – – – – A30
A*3022 A30 – – – – – – – A30
A*3101 A31 A31(19) A31 [94–98]a 23 A31 [90], A30 [3], 3517 A31 58 Training – A31
A19 [1]
A*3102 A31 A31(19)b – – A31 [100]c 17 – – A31
A*3103 A31 – – – A31 [100]c 2 – – A31
A*3104 A31 A31(19) – – – – – – A31
A*3105 A31 A31(19) – – – – – – A31
A*3106 A31 – – – – – – – A31
A*3107 Undefined – – – – – – – Not assignede NN: A32, A23, A9
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 1 Continued
International Cell
Exchange, UCLA NMDP IHWS13 data NN
HLA allele Expert assigned assigned Assigned type [%] tested type [%] tested Assignment tested type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
A*3115 A31 – – – – – – – A31
A*3116 A31 – – – – – – – A31
A*3117 A31 – – – – – – – A31
A*3118 A31 – – – – – – – A31
A*3201 A32 A32(19) A32 [97–99]a 20 A32 [94] 3441 A32 50 Training – A32
A*3202 A32 A32(19) – – A32 [100]c 3 – – Not assignede NN: A32
A*3203 A32 – – – A32 [67], blank [33]c 3 – – A32
A*3204 A32/A3 – – – A3 [75], A19 [13], 8 A‘3204’ 1 Not assignede A3 with most A32
A32 [13]c sera reactive
(ihw13); NN: A32,
A3
A*3205 A32 – – – – – – – A32
A*3206 A32 – – – – – – – A32
A*3207 A32 – – – A32 [100]c 1 – – A32
A*3208 A32 – – – A32 [100]c 2 – – A32
A*3209 A32 – – – – – – – A32
A*3210 A32 – – – – – – – A32
A*3211Q A32 – – – – – – – A32 Not expected to be
expressed
A*3212 A32 – – – – – – – A32
A*3213 A32 – – – A32 [100]c 1 – – A32
A*3214 A32 A32(19) – – – – – – A32
A*3215 A32 – – – – – – – A32
A*3301 A33 A33(19) A33 [97–100] 10a A33 [87], A19 [3], 687 A33 19 Training – A33
blank [4]
A*3303 A33 A33(19) A33 [95–100]a 36 A33 [95], A34 [1] 887 A33 27 Training – A33
A*3304 A33 – – – A33 [50], blank [50]c 2 – – A33
A*3305 A33 A33(19) – – A33 [92]c 13 A33 1 A33 ihw13: short A33
HLA alleles and serologic types
109
Table 1 Continued
110
International Cell
Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 1 Continued
International Cell
Exchange, UCLA NMDP IHWS13 data NN
HLA allele Expert assigned assigned Assigned type [%] tested type [%] tested Assignment tested type >0.55 Comments
A*6601 A66 A66(10) A66 [37–59], A‘6601’ 14 A26 [61], A66 [20], 799 A66 19 Training – A10, A66 ihw13: A‘6601’
[22–42], A26 [15– A34 [8], A10 [3], pattern – different
18], A10 [2–7]a A25 [1] from A‘6602’;
reactive with A34 1
66 sera
A*6602 A66 A66(10) A‘6602’ [35–65], 8 A66 [38], A34 [27], 205 A66 2 A66 ihw13: A‘6602’, short
A66 [15–42], A34 A10 [10], A74 [5], A66
[7–18], A10 [4]a A26 [4]
A*6603 A10 A10 – – A66 [32], A34 [18], 28 – – A10f Short A10; NN: A26
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
A10 [7], A26 [7]
A*6604 A66 – – – – – – – A66
A*6605 A26 – – – A26 [100]c 1 – – A26
A*6606 A66 A66(10) – – – – – – A66
A*6801 A68 A68(28) A68 [53–68], A28 34 A28 [63], A68 [27] 2736 A68 49 Training – A28, A68
[31–45]a
A*6802 A68 A68(28) A68 [55–65], A28 15 A28 [72], A68 [19], 2327 A68 18 Training – A28, A68
[32–43]a A69 [1]
A*6803 A68 A68(28)b A68 [47–66], A28 16 A28 [63], A68 [28] 202 A68 4 A68
[34–48]a
A*6804 A68 A68(28) – – A28 [75], A68 [25]c 4 – – A68
A*6805 A68 A68(28) – – A28 [53], A68 [29] 59 A28 1 A68 ihw13: possibly A68,
but cell also A2
positive
A*6806 A68 – – – A28 [50], A68 [50]c 2 – – A68
A*6807 A68 – – – Blank [100]c 1 – – A68
A*6808 A68 A68(28) A68 [38–45], A28 [53] 2 A28 [100]c 2 – – A68
A*6809 A68 – – – A68 [100]c 1 – – A68
A*6810 A68 A28b – – Blank [50], A1 [50]c 2 A28 1 A68 ihw13: possibly A68,
but cell also A2
positive
A*6811N Not expressed Null – – – – – – NT
A*6812 A28 A28 – – A28 [50], blank [50]c 6 – – A68 Short A28
A*6813 A68 – – – – – – – A68
A*6814 A68 – – – – – – – A68
A*6815 A68 – – – – – – – A68
A*6816 A68 A68(28) – – – – – – A68
HLA alleles and serologic types
111
Table 1 Continued
112
International Cell
Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
R. Holdsworth et al. HLA alleles and serologic types
Updated NMDP data. In some cases, the information reported in previous dictionaries has changed. Cells have been excluded from this study in some cases because their HLA typing has changed.
next to A1 or A24
Assignments made using the expectation
maximization algorithm
Comments
NN: A74
The 2008 data set includes only those typings from US
volunteer donors where both serologic and allele-level results
have been reported for the HLA-A, -B, -C, -DRB1, or -DQB1
loci. As in past versions of the dictionary, the expectation
maximization (EM) algorithm was used to obtain the cor-
Training – A80
Not assignede
cribe the use of the EM algorithm and the nuances of the data.
A74
A74
NN
NT
NT, not tested; NN, neural network; HLA, human leukocyte antigen; WHO, World Health Organization; NMDP, National Marrow Donor Program.
Cells
1
–
–
If a primary specificity is provided by the NN, other specificities >0.4 are shown in the comments column.
A74 [33], A33 [33],
–
–
11
–
–
–
–
–
–
–
–
A*0208 of 100%.
Expert assigned
Not expressed
A74
A80
A*7410
A*7411
A*8001
g
a
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170 113
Table 2 HLA-B alleles and their serologic designationsg
114
International Cell Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
B*0729 B7 – – – – – – – B7
B*0730 B7 B7 – – – – – – B7 B7 variant
B*0731 B7/B42 B7/B42 – – – – – – B7 B7x42, short B7
B*0732 B7/blank – – – – – – – B7 B blank
B*0733 B7 – – – B7 [100]b 1 – – B7
B*0734 B7 – – – – – – – B7
B*0735 B7 – – – – – – – B7
B*0736 B7 – – – B7 [100]b 1 – – B7 Bw4 positive
B*0737 B7 – – – – – – – B7
B*0738 Undefined – – – – – – – Not assignede
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B*0739 B7 – – – – – – – B7
B*0740 B7 B7 – – – – – – B7
B*0741 B7 – – – – – – – B7
B*0742 B7 – – – – – – – B7
B*0743 B7 – – – – – – – B7
B*0744 B7 – – – – – – – B7
B*0745 B7 – – – – – – – B7
B*0746 B7 B7 – – – – – – B7
B*0747 B7 – – – – – – – B7
B*0748 B7 – – – – – – – B7
B*0749N Not expressed Null – – – – – – NT
B*0750 Undefined – – – – – – – NT NN: B7
B*0751 B7 – – – – – – – B7
B*0752 B7 – – – – – – – B7
B*0753 B7 – – – – – – – B7
B*0754 B7 – – – – – – – B7
B*0755 B7 – – – – – – – B7
B*0756 B7 – – – – – – – B7
B*0757 B7 B7 – – – – – – B7
B*0758 B7 B7 – – – – – – B7
B*0801 B8 B8 B8 [100]a 9 B8 [99] 6518 B8 61 Training – B8
bd
B*0802 B8 B8 – – 2 B‘0802’ 1 Not assignede B8 Bw4; ihw13: B8
Bw4 with extra
reactions; NN: B8
B*0803 B8 B8 – – B8 [100]b 1 – – Not assignede B8 Bw4
B*0804 B8/blank – B8 [51–71], B59 [6–7] 3 B8 [80], blank [20]b 5 B8 1 B8 Blank Bw6; ihw13:
short B8
bd
B*0805 B8 – – – 1 – – B8
HLA alleles and serologic types
115
Table 2 Continued
116
International Cell Exchange, UCLA NMDP IHWS13 data NN
B*0806 B8 B8 – – B8 [100]b 1 – – B8
B*0807 B8 B8 – – B8 [100]b 1 – – B8
B*0808N Not expressed Null – – – – – – NT
B*0809 B8 B8 – – B8 [100]b 11 B8 2 B8
HLA alleles and serologic types
B*0810 B8 B8 – – – – – – B8 Short B8
B*0811 B8 – – – B8 [100]b 3 – – B8
bd
B*0812 B8 – – – 1 – – B8
B*0813 B8 – – – B8 [100]b 1 – – B8
B*0814 B8 – – – – – – – B8
B*0815 B8 B8 – – – – B8 1 B8
B*0816 B8 B8 – – – – – – B8
B*0817 Undefined – – – – – – – Not assignede B blank; NN: B8
B*0818 B8 B8 – – – – – – B8
B*0819N Not expressed Null – – – – – – NT
B*0820 B8 – – – – – – – B8
B*0821 B8 – – – – – – – B8
B*0822 B8 – – – – – – – B8
B*0823 B8 – – – – – – – B8
B*0824 B8 – – – – – – – B8
B*0825 B8 – – – – – – – B8
B*0826 B8 – – – – – – – B8
B*0827 B8 – – – – – – – B8
B*0828 B8 – – – – – – – B8
B*0829 B8 B8 – – – – – – B8
B*0830N Not expressed Null – – – – – – NT
B*0831 B8 – – – – – – – B8
B*0832 B8 – – – – – – – B8
B*0833 B8 – – – – – – – B8
B*1301 B13 B13 B13 [95–99]a 4 B13 [97] 238 B13 9 Training – B13
B*1302 B13 B13 B13 [98–100]a 9 B13 [99] 1307 B13 17 Training – B13
B*1303 B49/B15 – – – B13 [100]b 1 – – B13 B15x21–Bw4; B21
variant with some
B15 sera reactive
B*1304 B49/B15 B15/B21 B21 [22–38], B49 [15], 2 – – B‘1304’ 1 B13 B15x21–Bw4, similar
B15 [7–17], B15x21 to B*1303; ihw13:
[0–15], B50 [5–11], new pattern, also
B63 [0–8], B77 [4–7] B49, B63 and B77
reactivity
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B*1316 B13 – – – – – – – B13
B*1317 B13 – – – – – – – B13
B*1318 B13 – – – – – – – B13
B*1319 B13 – – – – – – – B13
B*1320 B13 – – – – – – – B13
B*1401 B64 B64(14) B14 [49–58], B64 8 B14 [72], B64 [10], 1003 B64 11 Training – B14
[32–43], B65 B65 [10]
[2–10]a
B*1402 B65 B65(14) B65 [50–54], B14 9 B14 [71], B65 [25], 2244 B65 22 Training – B14
[45–47], B64 [1–3]a B64 [2]
B*1403 B14 B14c – – B14 [50], B65 [35] 40 – – B14
B*1404 B14 – – – B14 [67], B64 [33]b 3 – – B14
B*1405 B14 – – – B14 [40], blank [60]b 5 B65 1 B14
B*1406 B14 B14 – – B14 [100]b 8 – – B14 B65
B*1407N Not expressed Null – – – – NT
B*1501 B62 B62(15) B62 [93–98]a 30 B62 [96], B15 [2] 1906 B62 64 Training – B15 B62
B*15010102N Not expressed Null – – – – – – NT
B*1502 B75 B75(15) B75 [79–86], B15 16 B75 [62], B62 [22], 1035 B75 18 Training – B15 B75
[8–11], B62 [5–12] B15 [7]
B*1503 B72 B72(70) B70 [47–61], B72 17 B70 [61], B72 [10], 2569 B72 25 Training – B70 B72
[31–45]a B35 [2], B62 [1],
blank [11]
B*1504 B62 B62(15) B62 [90], B15 [5], 1 B62 [69], B15 [10] 29 B62 1 B62
B75 [4]a
B*1505 B62 B62(15) B62 [88] 1 B62 [64], B15 [18] 22 B62 3 B62
B*1506 B62 B62(15) – – B62 [81]b 13 – – B62
B*1507 B62 B62(15) B62 [93] 2 B62 [79] 101 B62 2 Training – B15 B62
HLA alleles and serologic types
117
Table 2 Continued
118
International Cell Exchange, UCLA NMDP IHWS13 data NN
B*1508 B75/B62 B75(15) B75 [30–48], B15 2 B62 [20], B15 [18], 45 B75 3 B15
[19–35], B62 B75 [18]
[6–19], B‘1508’
[11–14]
HLA alleles and serologic types
B*1509 B70 B70 – – B70 [53], blank [33] 65 B71 2 Training – B70 B71
B*1510 B71 B71(70) B70 [41–49], B71 15 B70 [49], B35 [4], B72 1204 B71 7 Training – B70 B71
[41–47]a [2], B71 [2], B75 [1],
B15 [1], blank [13]
B*1511 B75 B75(15) B75 [31–51], B15 3 B62 [27], B75 [21], 68 B75 4 B15
[21–38], B46 B46 [15], B15 [15]
[6–12], B‘1511’
[0–19]
B*1512 B76 B76(15) B76 [76–88], B45 5 B76 [29], B62 [18], 17 B76 2 Training – B15 B76
[3–6] B75 [6], B15 [29]b
B*1513 B77 B77(15) B77 [46–53], B63 2 B77 [21], B63 [19], 116 B77 7 Training – B15 B77
[0–16] B15 [15], B75 [12],
blank [13], B62 [8],
B53 [6]
B*1514 B76 B76(15) B76 [23], B45 [20], 1 B45 [80], B44 [20]b 5 B76 1 B62
B15 [20], B70 [6],
B63 [5]
B*1515 B75/62 B62(15) B75 [43–57], B62 10 B62 [49], B75 [28], 138 B75 1 B15 ihw13: short B75
[31–42], B15 B15 [13]
[8–15]a
B*1516 B63 B63(15) B63 [96–97]a 8 B63 [80], B57 [3], 816 B63 3 Training – B15 B63
B15 [3]
B*1517 B63 B63(15) B63 [92–96] 5 B63 [88], B15 [3], 797 B63 11 Training – B15 B63
B57 [1]
B*1518 B71 B71(70) B70 [52–64], B71 11 B70 [51], blank [34], 552 B71 8 Training – B70 B71
[28–34]a B71 [3]
B*1519 B76 B76(15) B76 [29], B15 [19], 1 B70 [50], B76 [50]b 2 – – B76
B45 [11], B62 [8],
B75 [7]
B*1520 B62 B62(15) B62 [73], B15 [18], 1 B62 [100]b 10 B62 1 B62 ihw13: short B62
B75 [5]
B*1521 B75 B75(15) B75 [80–88], B15 21 B75 [55], B62 [12], 132 B75 9 Training – B15 B75
[6–9], B62 [3–10] B15 [7]
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
e
B*1523 B70/B5/blank – B‘1523’ [17], B5 2 Blank [50], B70 [17], 12 B‘1523’ 2 Not assigned B5x70–Bw4, B5/53/
[14–15], B77 B51 [17], B53 [8]b 77 variant; NM5;
[7–11], B70 [7–9], ihw13: new
B15 [5–8] pattern, short B71-
Bw4; NN: B70 B71
B*1524 B62 B62(15) B62 [45–48], B‘1524’ 4 B62 [44], blank [22] 54 B62 8 B15 B62 Bw4
[23–24], B15
[21–22], B77 [4–6],
B63 [2–3]
B*1525 B62 B62(15) B62 [86–94], B75 10 B62 [74], B75 [8], 116 B62 1 Training – B15 B62 ihw13: short B62,
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
[2–10]a B15 [7] short B75
B*1526N Not expressed Null – – – – – – NT
B*1527 B62 B62(15) B62 [97]a 1 B62 [76], B15 [7] 76 B62 2 Training – B15 B62 ihw13: short B62,
short B75
B*1528 B62 B62(15)c – – B62 [80], B15 [20]b 5 – – B62
B*1529 B70 B15 B70 [54–58], B15 2 Blank [71], B70 [19] 21 B71 2 B71
[11–12], B71 [7–10]
B*1530 B62 B62(15)c B62 [63–86], B75 3 B62 [64], B15 [17] 98 B62 3 Training – B15 B62 ihw13: short B62,
[4–13], B15 [12–19] short B75
B*1531 B75 B75(15) – – B75 [38], B62 [38]b 13 B75 1 B75 ihw13: short B75
B*1532 B62 B62(15) – – B62 [100]b 5 – – B62
B*1533 B62 B15 – – – – – – B62 B62
B*1534 B62 B62(15)c – – B62 [100]b 8 – – B62 Normal B62
B*1535 B62 B62(15)c B62 [86–93], B75 14 B62 [79] 34 B62 5 Training – B15 B62
[5–7]a
B*1536 Undefined – – – B13 [100]b 3 – – B15 Bw4 positive, NN:
B77
B*1537 B70 B70c B70 [46], B71 [11], 2 Blank [54], B70 [30] 24 – – B71
B78 [9]
B*1538 B62 – – – B62 [100]b 3 – – B62 B62 variant, also
reactive with B52
sera
B*1539 B62 B62(15)c B62 [92–98] 2 B62 [84], B15 [13]b 38 B62 3 B62
B*1540 B62/blank – – – Blank [61], B70 [10], 26 – – B62 Short B62
B62 [8]
B*1542 B15 – – – – – – – B62 Short B15; reactive
with some B22 sera
HLA alleles and serologic types
119
Table 2 Continued
120
International Cell Exchange, UCLA NMDP IHWS13 data NN
B*1546 Undefined B72(70) – – B50 [50], B72 [25]b 4 – – Not assignede NN: B15 B62
B*1547 B70/blank – – – Blank [57], B35 [14]b 14 – – B72 B48, all B15 sera
negative
B*1548 B62 B62(15) – – B62 [100]b 3 – – B62
B*1549 B72 – – – – – – – B72
B*1550 B62 – – – – – – – B62
B*1551 B70 B70 – – B35 [100]b 1 – – B71
B*1552 Undefined B15 – – Blank [67]b 3 – – B71 B15
B*1553 Undefined – – – – – – – Not assignede
B*1554 B72 – – – B70 [50], B72 [50]b 2 – – B72
B*1555 B15 B15 – – – – – – B15f B15 Bw6; NN: B75
B*1556 B62 – – – – – – – B62
B*1557 B62 – – – – – – – B62
B*1558 B62 B62(15) – – B62 [100]b 3 – – B62 B15 or B62
B*1560 B62 – – – – – – – B62
B*1561 B72 – – – – – – – B72
B*1562 Undefined – – – B62 [67]b 3 – – Not assignede NN: B70 B72
B*1563 B62 – – – B62 [100]b 2 – – B62
B*1564 B71 – – – – – – – B71
B*1565 B62 – – – B62 [100]b 2 – – B62
B*1566 B62 – – – B62 [100]b 1 – – B62
B*1567 B63 – – – – – – – B63 Bw4 positive
B*1568 Undefined B35 – – – – – – Not assignede NN: B70 B72
B*1569 B72 – – – – – – – B72
B*1570 B62 B62(15) – – – – B62 1 B62 ihw13: short B62,
short B75
B*1571 B62 B62(15) – – B62 [83], B75 [17]b 6 – – B62
B*1572 B71 – – – – – – – B71
B*1573 B62 B62(15) – – B62 [100]b 1 – – B62
B*1574 B72 – – – – – – – B72
B*1575 B62 – – – B62 [100]b 1 – – B62
B*1576 Undefined – – – – – – – Not assignede NN: B15
B*1577 B62 – – – – – – – B62
B*1578 B62 B15 – – – – – – B62
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B*1589 B77 – – – – – – – B77
B*1590 B71 – – – – – – – B71
B*1591 Undefined – – – – – – – Not assignede NN: B70, B72, B12
B*1592 B62 – – – – – – – B62
B*1593 B71 B71(70) – – – – – – B71
B*1594N Not expressed Null – – – – – – NT
B*1595 B63 – – – – – – – B63
B*1596 B62 B62(15) – – – – – – B62
B*1597 B62 – – – – – – – B62
B*1598 B72 – – – – – – – B72
B*1599 B71 – – – – – – – B71
B*9501 Undefined – – – – – – – Not assignede NN: B15, B46
B*9502 B62 B62(15) – – – – – – B62
B*9503 B70 B70 – – – – – – B72
B*9504 B62 – – – – – – – B62
B*9505 B62 – – – – – – – B62
B*9506 Undefined – – – – – – – Not assignede NN: B15, B62
B*9507 B62 B62(15) – – – – – – B62
B*9508 B71 B71(70) – – – – – – B71
B*9509 B62 – – – – – – – B62
B*9510 B62 – – – – – – – B62
B*9511N Not expressed Null – – – – – – NT
B*9512 B75 B15 – – – – – – B75
B*9513 B62 – – – – – – – B62
B*9514 B70 B70 – – – – – – B71
B*9515 B70 – – – – – – – B70
B*9516 B62 – – – – – – – B62
B*9517 B62 – – – – – – – B62
HLA alleles and serologic types
121
Table 2 Continued
122
International Cell Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B*2704 B27 B27 B27 [98]a 1 B27 [97] 31 B27 7 B27
B*2705 B27 B27 B27 [99–100] 6 B27 [99] 1194 B27 22 Training – B27
B*2706 B27 B27 B27 [97–99]a 10 B27 [97] 29 B27 6 B27 Previously also
named B*2722
B*2707 B27 B27 – – B27 [100]b 49 B27 5 B27
B*2708 B2708/B27/B7 B2708 B2708 [36–58], 3 B27 [31], B7 [34], 32 B2708 1 B27 B7 variant, most B27
B7 [19–41], B27 blank [16], B2708 sera negative;
[11–19] [9]b ihw13: also B73 B7
blank
B*2709 B27 B27 B27 [100] 1 B27 [100]b 15 – – B27
B*2710 B27 B27 – – B27 [100]b 5 – – B27
B*2711 B27 B27 – – B27 [100]b 2 – – Not assignede B27 variant, extra
reactivity with B40
sera; NN: B27
B*2712 Undefined B27 – – Blank [78], B60 [9], 23 Blank 1 Not assignede Blank Bw6; B27 sera
B27 [4], B61 [4]b negative, B7 1 27
(140) sera positive;
ihw13: blank, B61
B27–Bw6; NN: B27
B*2713 B27 B27 – – – – – – B27
B*2714 B27 B27c – – B27 [100]b 14 – – B27
B*2715 B27 – – – – – – – B27 Blank Bw4
B*2716 B27 – – – – – – – B27 Short B27, some B40
sera reactive
B*2717 B27 B27 – – – – – – B27 Normal B27
B*2718 Undefined – – – Blank [100]b 2 – – Not assignede Bw6 positive
B*2719 B27 B27 – – – – – – B27 Normal B27
B*2720 B27 B27 – – – – – – B27
HLA alleles and serologic types
123
Table 2 Continued
124
International Cell Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
b
B*3518 B35 B35 – – B35 [100] 1 – – B35
B*3519 B35/blank B35 – – B35 [40], B70 [20], 5 Blank 2 B35 ihw13: new pattern,
B77 [20]b blank, very short
B35
B*3520 B35 B35 – – B35 [42], blank [13] 23 B35 5 B35
B*3521 B35/B78 – – – B35 [42], B78 [33], 12 B78 1 B35 ihw13: B35/78 variant
blank [25]b
B*3522 B35 – – – B35 [100]b 2 – – B35
B*3523 B35 B35c B35 [84–88] 4 B35 [92]b 13 B35 1 B35
B*3524 B35 – – – B35 [75], B78 [25]b 8 – – B35
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B*3525 B35 B35c – – B35 [33], blank [67]b 3 B35 1 B35 ihw13: short B35
B*3526 B35 – – – – – – – B35
B*3527 B35 B35 – – B35 [100]b 2 – – B35
B*3528 B35 – – – B35 [50], blank [43]b 14 – – B35
B*3529 B35 B35 – – B35 [100]b 2 – – B35
B*3530 B35 B35 – – B35 [100]b 7 – – B35 Normal B35
B*3531 B35 – – – Blank [67], B61 [17], 6 B35 1 B35 ihw13: short B35;
B48 [17]b reactive with few
B40 and B35 sera,
Korean
B*3532 B35 B35 – – B35 [100]b 2 – – B35
B*3533 B35 – – – – – – – B35
B*3534 B35 – – – B35 [100]b 1 – – B35
B*3535 B35 B35 – – – – – – B35
B*3536 B35 – – – B35 [100]b 1 – – B35
B*3537 B35 – – – B35 [100]b 1 – – B35
bd
B*3538 B35 – – – 1 – – B35
B*3539 B35 – – – – – – – B35
B*3540N Not expressed Null – – – – – – NT
B*3541 B35 B35 – – B35 [100]b 3 – – B35
B*3542 B35 B35 – – – – – – B35 Normal B35
B*3543 B35 B35 B35 [95–97]a 3 B35 [63], B70 [12] 379 B35 2 Not assignede Previously B*1522;
NN: B35
B*3544 Undefined B35 – – – – – – Not assignede Previously B*1559
B*3545 B35 – – – – – – – B35
B*3546 B35 B35 – – – – – – B35
B*3547 B35 – – – B35 [100]b 1 – – B35
B*3548 B35 – – – – – – – B35
HLA alleles and serologic types
125
Table 2 Continued
126
International Cell Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
c b
B*3704 B37 B37 – – B37 [50], blank [50] 2 B37 1 B37 B37 variant, reactive
with few B37 and
B18 sera
B*3705 Blank – – – – – – – Not assignede Blank Bw6, B37, and
Bw4 sera negative,
Korean; NN: B37
B*3706 B37 – – – – – – – B37
B*3707 Undefined – – – – – – – Not assignede
B*3708 B37 B37 – – – – – – B37
B*3709 B37 B37 – – – – – – Not assignede NN: B37
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B*3710 B37 B37 – – – – – – B37
B*3711 Undefined – – – – – – – Not assignede NN: B37
B*3712 B37 – – – – – – – B37
B*3713 B37 – – – – – – – B37
B*3801 B38 B38(16) B38 [96–100]a 14 B38 [94], B16 [1], 2317 B38 43 Training – B16 B38
B39 [1]
B*3802 B38 B38(16) B38 [91–99]a 15 B38 [87], B39 [2], 788 B38 15 Training – B16 B38 ihw13: different from
B16 [2] B*3801
B*3803 B38 B16 – – Blank [100]b 1 – – Not assignede B16 Bw4, B38, and
B39 sera negative;
NN: B16 B38
B*3804 B38 – – – – – – – B38
B*3805 B38 B38(16) – – – – – – B38 Normal B38
B*3806 B38 – – – – – – – B38
B*3807 B38 – – – – – – – B38
B*3808 B38 – – – – – – – B38
B*3809 B38 B16c – – – – – – B38 B16–Bw4, on cell
VOA Ter 299
B*3810 B38 – – – – – – – B38
B*3811 B38 – – – – – – – B38
B*3812 B38 B38(16) – – – – – – B38
B*3813 B38 – – – – – – – B38
B*3814 B38 – – – – – – – B38
B*3815 B38 B38(16) – – – – – – B38
B*3816 B38 – – – – – – – B38
B*3901 B3901/B39 B3901 B39 [96–99]a 7 B39 [95] 476 B39 21 Training – B16 B39
B*39010102L Low B39 Low B39 – – – – Identical to B*3901
HLA alleles and serologic types
127
Table 2 Continued
128
International Cell Exchange, UCLA NMDP IHWS13 data NN
B*3902 B3902/B39 B3902 B39 [97–99]a 7 B39 [87] 96 B39 5 Not assignede ihw13: short B39; NN:
B16 B39
B*3903 B39 B39(16) – – B39 [89] 19 B39 1 B39
b
B*3904 B39 B39(16) – – – – – B39
HLA alleles and serologic types
B*3905 B39 B39c B39 [89–92], B16 17 B39 [82] 245 B39 4 B39 B39 variant, ST-16;
[4–7], B38 [1–5]a ihw13: B39 and
B38 sera positive
B*3906 B39 B39(16) B39 [96–99] 6 B39 [94] 508 B39 8 Training – B16 B39
B*3907 B16 – – – Blank [100]b 1 – – B16
B*3908 B39 B39(16) B39 [86–91], B16 4 B39 [48], blank [41] 57 B39 1 Not assignede ihw13: B39 and B38
[3–5] sera positive; NN:
B16
B*3909 B39 B39(16) B39 [96–99] 6 B39 [100]b 29 B39 2 B39
B*3910 B39 B39(16) B39 [98]a 4 B39 [82], blank [16] 127 B39 5 B39
B*3911 B39 B39(16)c – – B39 [79], blank [14]b 29 – – B39
B*3912 B39 B39(16) – – B39 [100]b 1 B39 1 B39
B*3913 B39 B39(16) – – B39 [40], blank [40]b 5 – – Not assignede NN: B16, B39
B*3914 B39 – – – B39 [100]b 4 – – B39
B*3915 B39 B39(16)c – – B39 [100]b 6 B39 1 B39
B*3916 B39 – – – – – – – B39
B*3917 B39 – – – B39 [100]b 1 – – Not assignede NN: B39, B16
B*3918 B39 – – – – – – – B39
B*3919 B39 B39(16)c – – Blank [100]b 1 B39 1 B39
B*3920 B39 – B39 [73], B16 [16]a 1 Blank [67], B38 [33]b 3 – – B16f NN: B38
bd
B*3922 B39 – – – 1 – – B39
B*3923 B39 B39(16) – – – – – – Not assignede NN: B16, B39
B*3924 B39 B39(16) – – B39 [97]b 30 B39 1 B39 Normal B39
B*3925N Not expressed Null – – – – – – NT
B*3926 B39 – – – – – – – B39
B*3927 B39 B39(16) – – – – – – B39 Normal B39
B*3928 B39 – – – – – – – B39
B*3929 B39 – – – – – – – B39
B*3930 B39 – – – – – – – B39
B*3931 B39 – – – B39 [100]b 2 – – B39
B*3932 B16 – – – – – – – B16f NN: B39
B*3933 B39 – – – – – – – B39
B*3934 B39 B39(16) – – – – – – B39
B*3935 B39 – – – B39 [100]b 1 – – B39
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
e
B*3936 Undefined – – – – – – – Not assigned NN: B39, B16, B14
B*3937 B39 – – – – – – – B39
B*3938Q B39 – – – – – – – B39 Not expected to be
expressed
B*3939 B39 – – – – – – – B39
B*3940N Not expressed Null – – – – – – NT
B*3941 B39 B39(16) – – – – – – B39
B*3942 B39 – – – – – – – B39
B*4001 B60 B60(40) B60 [96–98]a 37 B60 [93], B40 [4], 3854 B60 48 Training – B40 B60
B61 [2]
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B*4002 B61 B61(40) B61 [75–95], B40 24 B61 [80], B60 [8], 1460 B61 33 Training – B40 B61
[3–19], B60 [2–21]a B40 [6]
B*4003 B61 B61(40)c – – B61 [62], B60 [23] 31 B61 1 B61
B*4004 B61 B61(40)c – – B61 [47], B60 [12] 57 B61 3 B61
B*4005 B4005/B50 B4005 B4005 [41–57], B50 3 B50 [34], B4005 [12], 293 – – B61 BN21, B21 variant
[28–36], B21 [5–9] blank [23], B61 [7],
B70 [4], B21 [4],
B60 [4]
B*4006 B61 B61(40) B61 [87–90], B40 [4], 6 B61 [75], B60 [5], 585 B61 17 Training – B40 B61
B60 [4–8]a B40 [5]
B*4007 B60 B60(40)c – – B60 [100]b 12 – – B60 B‘Fu’
B*4008 B61/blank – B61 [20–27], B40 3 Blank [71], B61 [12], 138 B61 2 B61 B40x48 variant, only
[20–30], B‘4008’ B40 [9] reactive with some
[9–10], B48 [2–14] B40 1 48 (17)
CREG sera
B*4009 B61 B61(40) – – B61 [60], B40 [20]b 5 B61 1 B61
B*4010 B60 B60(40) B60 [75–93], B40 10 B60 [43], B61 [25], 28 B60 2 B60 Short B60, B48 like
[14–15], B61 [3–8], B40 [14], blank
B48 [2–3]a [11]b
B*4011 B61 B61(40)c – – B61 [71], B60 [26]b 38 B61 2 B61
B*4012 B60/B48 – B48 [28–34], B70 [7– 3 B48 [37], B60 [26], 19 – – Not assignede B48x70, some
20], B40 [11], B72 blank [21], B40 reactivity with B40
[10], B‘4012’ [8], [16]b 1 48 and B15 1 70
B61 [5] CREG sera; NN:
B48
B*4013 Undefined – – – Blank [100]b 1 – – Not assignede B40 Bw4; NN: B61
B40
B*4014 B60 B60(40) – – B60 [100]b 3 – – B40f NN: B60
HLA alleles and serologic types
129
Table 2 Continued
130
International Cell Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
b
B*4040 B61 – – – B61 [100] 1 – – B61
B*4042 B60 – – – – – – – B60
B*4043 B60 – – – – – – – B60
B*4044 B61 – – – – – – – B61
B*4045 B60 – – – – – – – B60
B*4046 B60 – – – – – – – B60
B*4047 B40 B40 – – – – – – Not assignede B40 Bw4; short B60,
Bw4pos: NN: B40,
B60
B*4048 B60 B60(40) – – – – – – B60
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B*4049 B60 – – – – – – – B60
B*4050 B61 B61(40) – – – – – – B61
B*4051 Undefined – – – – – – – Not assignede NN: B40
B*4052 B60 B60(40) – – – – – – B60
B*4053 B61 B61(40) – – – – – – B61
B*4054 B60 B60(40) – – – – – – B60
B*4055 B60 – – – – – – – B60
B*4056 B61 B61(40) – – – – – – B61
B*4057 B61 – – – – – – – B61
B*4058 B40 – – – – – – – B40
B*4059 B40 – – – – – – – B40f NN: B60
B*4060 Undefined – – – – – – – Not assignede NN: B60, B40
B*4061 B60 – – – – – – – B60
B*4062 B60 – – – – – – – B60
B*4063 B60 – – – – – – – B60
B*4064 B61 B40 – – – – – – B61
B*4065 B60 – – – – – – – B60
B*4066 B60 – – – – – – – B60
B*4067 B60 – – – – – – – B60
B*4068 Undefined – – – – – – – Not assignede NN: B40, B61
B*4069 B60 – – – – – – – B60
B*4070 B61 B61(40) – – – – – – B61
B*4071 B61 – – – – – – – B61
B*4072 B60 – – – – – – – B60
B*4073 B60 – – – – – – – B60
B*4074 B60 – – – – – – – B60
B*4075 B61 – – – – – – – B61
B*4076 B60 – – – – – – – B60
HLA alleles and serologic types
131
Table 2 Continued
132
International Cell Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
c b
B*4409 B45 B45(12) – – B45 [92] 12 B45 1 B12 B44Bw6, will be
typed as B45 or
B12; most B44- and
B45-specific sera
negative
B*4410 B44 B44(12)c – – B44 [70] 37 – – B12f NN: B44
B*4411 B44 – – – B44 [100]b 2 – – B44
B*4412 B44 B44(12) – – – – – – B44
B*4413 B44 B44(12) – – – – – – B44
B*4414 B44 B44(12) – – – – – – B44 Short B44
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B*4415 B12 B12 – – – – – – B45 B45 Bw4, will be
typed as B44 or B12
B*4416 B47/B44 B47 B47 [52], B44 [12] 1 – – – – B44 B44x47, reactive with
most B47 and few
B44/12 sera
B*4417 B44 B44(12) – – B44 [100]b 1 – – B44
B*4418 B44 – – – B44 [100]b 1 – – B12f NN: B49
B*4419N Not expressed Null – – – – – – NT
B*4420 B44 – – – B44 [100]b 1 – – B44
B*4421 B44 – – – B44 [100]b 1 B44 2 B44 ihw13: blank or very
short B44
B*4422 B44 – – – B44 [100]b 1 – – B44
B*4423N Not expressed Null – – – – Blank 1 NT
B*4424 B44 – – – – – – – B44
B*4425 B44 – – – B44 [100]b 1 – – B44
B*4426 B44 – – – – – – – B44
B*4427 B44 B44(12) – – B44 [100]b 30 – – B44 Short B44
B*4428 B44 – – – – – – – B44
B*4429 B44 B44(12)c – – B44 [100]b 2 – – B44 Normal B44
B*4430 B44 – – – – – – – B44
B*4431 B44 B44(12) – – – – – – Not assignede Almost normal B44;
NN: B60, B40, B12
B*4432 B44 B44(12) – – – – – – B44 Short B44
B*4433 B44 – – – – – – – B44
B*4434 B44 – – – – – – – B44
B*4435 B44 – – – – – – – B44 Normal B44
B*4436 B44 – – – – – – – B44
bd
B*4437 B44 – – – 2 – – B44
HLA alleles and serologic types
133
Table 2 Continued
134
International Cell Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
B*4701 B47 B47 B47 [90–96] 3 B47 [50], B27 [5], 311 B47 12 Training – B47
blank [32]
B*4702 B47 B47 – – B47 [40], blank [40], 5 B61 1 Not assignede B47 Bw6, B47 1 13 1
B60 [20]b 27 sera negative,
B40 1 13 1 47 sera
positive; NN: B47
B*4703 B47 B47 B47 [70–77], B60 2 Blank [33], B47 [17], 6 B47 1 B47 B47 Bw4, B47 1 13
[4–9], B61 [7–8], B13 [17], B40 [17], sera negative, B40
B40 [6–7] B61 [17]b 1 13 sera positive
B*4704 Undefined – – – – – – – Not assignede NN: B47
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B*4705 B17 – – – – – – – B47
B*4801 B48 B48 B48 [90–100]a 26 B48 [78], B60 [6], 610 B48 11 Training – B48
B61 [2], B40 [2]
B*4802 B48/B70 B48 – – Blank [44], B35 [16], 39 B71 2 Not assignede B71 like; ihw13:
B70 [13], B48 [3] pattern identical to
B*1510; NN: B35
B*4803 B48 B48c B48 [97]a 1 B48 [66], B60 [13] 32 B48 1 B48
B*4804 B48 B48 – – B48 [50], B40 [25]b 4 – – B48 Normal B48
B*4805 B48 B48 – – – – – – Not assignede NN: B48, B7
B*4806 Undefined – – – – – – – Not assignede NN: B48
B*4807 B48 B48 – – B60 [42], B48 [33], 12 B48 2 B48
B61 [8]b
B*4808 Undefined – – – – – – – Not assignede NN: B7, B48
B*4809 B48 B48 – – – – – – B48
B*4810 B48 B48 – – – – – – B48
B*4811 B48 – – – – – – – B48
B*4812 B48 – – – – – – – B48
B*4813 Undefined – – – – – – – Not assignede NN: B48, B61
B*4814 B48 – – – – – – – B48
B*4815 B48 – – – – – – – B48
B*4816 B48 – – – – – – – B48
B*4817 Undefined B48/40 – – – – – – Not assignede NN: B48
B*4818 B48 – – – – – – – B48
B*4901 B49 B49(21) B49 [94–98]a 6 B49 [94], B50 [1], 3002 B49 22 Training – B21 B49
B21 [1]
B*4902 B49 B49(21) – – B49 [100]b 6 – – B49 Normal B49
B*4903 B49 – – – – – B49 1 Not assignede Short B49; NN:
B49, B21
HLA alleles and serologic types
135
Table 2 Continued
136
International Cell Exchange, UCLA NMDP IHWS13 data NN
B*5002 B45 B45(12) B45 [87–91], B50 [7], 2 B45 [96] 79 B45 3 Training B12 B45
B44 [5]a
B*5004 B50 B50(21) – – B50 [67]b 3 – – B50
B*5101 B51 B51(5) B51 [96–99] 40 B51 [96], B5 [2], 1899 B51 88 Training – B5 B51
B52 [1]
B*5102 B5102/B51 B5102 B51 [38–57], B5102 11 B51 [73], B53 [11], 218 B5102 5 B51 ihw13: short B51 with
[21–33], B53 B52 [6], B5102 [3], some B35 1 53
[8–16], B5 [4–7], B5 [3] sera reactive
B52 [3–7]
B*5103 B5103/B51 B5103 – – B51 [100]b 3 – – B51
B*5104 B51 B51(5)c – – B51 [75], B52 [12], 8 B51 1 B51
B5 [12]b
B*5105 B51 B51(5) B51 [45], B53 [33], 1 B51 [48], B53 [24], 25 B51 3 B51 ihw13: B5102, short
B5 [3], B52 [3] B52 [16] B51 with some B35
1 53 sera reactive
B*5106 B51 B51(5) B51 [82–88], B53 5 B51 [64], B53 [12], 42 B51 5 B51 B5, most B51 sera
[1–4], B52 [0–4], B52 [7] negative; ihw13:
B5102 [0–3]a short B51, distinct
pattern
B*5107 B51 B51(5) – – B51 [78], B52 [9] 68 B51 3 Training – B5 B51 ihw13: short B51,
distinct pattern
B*5108 B51 B51(5) B51 [96–99]a 3 B51 [77], B53 [4] 154 B51 4 Training – B5 B51
B*5109 B51 B51(5) – – B51 [86] 43 – – Training – B5 B51
B*5110 B51 – – – Blank [100]b 2 B51 1 B51 ihw13: B5102, short
B51 with some B35
1 53 sera reactive
B*5111N Not expressed Null – – – – – – NT
B*5112 B51/blank – – – – – – – B51 B ‘blank’, possibly not
expressed
B*5113 B51 – B51 [95–98]a 2 B51 [100]b 7 – – B51
B*5114 B51 B51(5)c – – B51 [88], B5 [12]b 17 B51 1 B51
B*5115 Undefined – – – – – – – Not assignede NN: B59
B*5116 B51 B5 – – B51 [100]b 1 – – B51
B*5117 B51 B51(5) – – – – – – B51
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B*5129 B51 B51(5) – – B51 [100]b 1 – – B51
B*5130 B51 – – – – – – – B51
d
B*5131 B51 B51(5) – – 1 – – B51
B*5132 B51 – – – – – – – B51
B*5133 B51 – – – – – – – B51
B*5134 B51 – – – – – – – B51
B*5135 B51 B51(5) – – – – – – B51
B*5136 B51 – – – – – – – B51
B*5137 B51 – – – – – – – B51
B*5138 B51 – – – – – – – B51
B*5139 B51 – – – – – – – B51
B*5140 B51 – – – – – – – B51
B*5141N Not expressed Null – – – – – – NT
B*5142 Undefined B44(12) – – – – – – Not assignede NN: B44, B12, B53
B*5143 B51 B51(5) – – – – – – B51
B*5144N Not expressed Null – – – – – – NT
B*5145 Undefined – – – – – – – Not assignede NN: B5, B51
B*5146 B51 B51(5) – – – – – – B51
B*5147 B51 – – – – – – – B51
B*5148 B51 – – – – – – – B51
B*5149 B51 – – – – – – – B51
B*5201 B52 B52(5) B52 [93–95] 13 B52 [82], B51 [7], 2823 B52 32 Training – B5 B52
B5 [2], B53 [1]
B*5202 B52 – – – B52 [100]b 2 – – B52 B15
B*5203 B52 – – – B52 [100]b 1 – – B52
B*5204 B52 B52(5) B52 [76], B5 [11] 1 – – – – B52 Normal B52
B*5205 B52 – – – – – – – B52
B*5206 B52 – – – – – – – B52
HLA alleles and serologic types
137
Table 2 Continued
138
International Cell Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B56 [25], blank
[25]b
B*5508 B56 B56(22) – – – – B56 2 B56
B*5509 B22 B22 – – – – – – B55 Short B22, B7 CREG
sera positive,
negative with B55
and B56 sera
B*5510 B55 B55(22) – – B55 [100]b 1 – – B22
B*5511 B55 – – – – – – – B55
B*5512 B55 B22 – – – – – – B55
B*5513 B55 – – – B55 [100]b 1 – – B55 B55v
B*5514 Undefined – – – – – – – Not assignede NN: B22, B55
B*5515 B55 B55(22) – – – – – – B55
B*5516 B55 B22 – – – – – – B55
B*5517 B55 – – – – – – – B55
B*5518 Undefined – – – – – – – Not assignede
B*5519 B55 – – – – – – – B55
B*5520 B22 – – – – – – – B22f NN: B55
B*5521 B55 – – – – – – – B55
B*5522 B22 B55(22) – – – – – – B22f NN: B56
B*5523 B55 – – – B55 [100]b 1 – – B55
B*5524 B55 – – – – – – – B55
B*5525 B55 – – – – – – – B55
B*5526 B55 – – – – – – – B55
B*5527 B55 – – – – – – – B55
B*5601 B56 B56(22) B56 [94–96] 5 B56 [72], B22 [5], B55 671 B56 23 Training – B22 B56
[3], blank [8]
HLA alleles and serologic types
139
Table 2 Continued
140
International Cell Exchange, UCLA NMDP IHWS13 data NN
B*5602 B56 B56(22) – – B56 [63], B55 [12], 8 B56 6 Training – B22 B56
blank [25]b
B*5603 B22/15 B22 – – B56 [65], B22 [6], 17 B56 1 Not assignede B22 variant, B55, B56
blank [12]b sera negative, B15
HLA alleles and serologic types
1 46 1 70 sera
reactive; in Asians
B*5604 B56 B56(22) B56 [88–93], B22 4 B56 [82], B54 [4], B22 28 B56 1 B56 Short B56s, some
[1–5]a [4], blank [11]b B56 and B22 sera
negative
B*5605 B56 B56(22) – – Blank [100]b 1 B56 4 B22 Short B56
B*5606 B78 B78 – – – – – – B22 B78 variant, some
B35 and B15 CREG
sera positive, all
B22 sera negative
B*5607 B56 B56(22) – – – – B56 1 Not assignede B56 Bw4, some B7
sera positive;
ihw13: B56 Bw4;
NN: B56, B22
B*5608 B56 – – – – – – – B56
B*5609 B56 – – – – – – – B56
B*5610 B55 B55(22) – – – – – – B55 Short B22, reactive
with B54 1 55 sera,
negative with B55
1 7 sera
B*5611 B56 B56(22) – – – – – – B56 Short B56
B*5612 B22 B55(22) – – – – – – B22
B*5613 B56 B56(22) – – – – – – B56
B*5614 B56 – – – – – – – B56
B*5615 B56 B56(22) – – – – – – B56
B*5616 B56 – – – – – – – B56
B*5617 B56 – – – Blank [100]b 1 – – B56
B*5618 Undefined – – – – – – – Not assignede NN: B22
B*5619N Not expressed Null – – – – – – NT
B*5620 B56 B56(22) – – – – – – B56
B*5701 B57 B57(17) B57 [87–98], B58 12 B57 [92], B17 [5], 3670 B57 28 Training – B17 B57
[1–7], B17 [1–6]a B58 [2]
B*5702 B57 B57(17) B57 [95–96]a 8 B57 [78], B17 [8] 65 B57 4 Training – B17 B57 ihw13: short B57
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 2 Continued
a
B*5703 B57 B57(17) B57 [96–98] 5 B57 [85], B17 [6], 412 B57 7 Training – B17 B57
B58 [6]
B*5704 B57 B57(17) – – B57 [67], B17 [7] 32 B57 1 B57 ihw13: short B57
B*5705 B57 – – – B57 [100]b 3 – – B57
B*5706 B57 – – – – – – – B57
B*5707 B57 – – – – – – – B57
B*5708 B57 B57(17) – – – – – – B57 Bw4 sera negative,
only strongly
reactive with B15 1
57 sera
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
B*5709 B57 – – – – – – – B57
B*5710 B57 – – – – – – – B57
B*5711 B57 – – – – – – – B57
B*5712 B57 – – – B57 [100]b 1 – – B57
B*5713 B57 – – – – – – – B57
B*5801 B58 B58(17) B58 [90–100]a 25 B58 [79], B57 [8], 2096 B58 28 Training – B17 B58
B17 [4]
B*5802 B58 B58(17) B58 [82–93]a 2 B58 [72], B57 [12], 837 B58 10 Training – B17 B58
B17 [3]
B*5804 B58 – – – B58 [100]b 1 – – B58
B*5805 B58 – – – – – – – B58
B*5806 B58 – – – B58 [100]b 1 – – B58
B*5807 B58 – – – – – – – B58
B*5808 B17/B5 B17 – – – – – – B5 B17 and some B5
sera reactive; NN:
B17
B*5809 B17 – – – – – – – B58 B57
B*5810N Not expressed Null – – – – – – NT
B*5811 B58 – – – – – – – B58
B*5812 B58 – – – – – – – B58
B*5813 B58 – – – – – – – B58
B*5814 B58 – – – – – – – B58
B*5815 B58 – – – – – – – B58
B*5901 B59 B59 B59 [92–95]a 9 B59 [45], blank [41] 123 B59 6 Training – B59
B*5902 B59 B59 – – – – – – B59
B*6701 B67 B67 B67 [86–90], B39 6 B39 [43], B67 [32], 81 B67 5 Training – B67 ihw13: pattern
[5–11]a B55 [8], blank [11] included in B22
B*6702 Undefined – – – B39 [100]b 1 – – Not assignede NN: B67
HLA alleles and serologic types
141
Table 2 Continued
142
International Cell Exchange, UCLA NMDP IHWS13 data NN
B*7301 B73 B73 B73 [81–87] 4 Blank [69], B73 [22] 106 B73 3 Training – B73 ihw13: pattern similar
to B2708
B*7801 B78 B78 B78 [83–90], B35 5 B78 [41], B35 [15], 210 B78 1 Training – B78
[1–9], B51 [1–6] B51 [10], B70 [4],
HLA alleles and serologic types
blank [19]
B*7802 B78 B78 – – B78 [25], B35 [25], 4 – – B78
B51 [25]b
B*7803 B78 – – – – – – – B78
B*7804 B35 – – – B35 [100]b 5 – – Not assignede NN B35
B*7805 Undefined – – – – – – – Not assignede NN B52
B*8101 B81 B81 B81 [81–90], B7 12 B7 [76], B81 [8] 657 B81 7 Training – B81
[10–18], B48 [0–3]a
B*8102 B81 B81 B81 [89–90], B7 [10], 2 – – – – B81
B48 [0–3], B60
[2–3]a
B*8201 B82 B82 B‘8201’ [28], B22 [9] 1 Blank [68], B45 [4], 146 B‘82’ 4 B56 B22x45, reactive with
B70 [4], B‘82’ [3], some B45 and B22
B65 [3] sera; ihw13:
pattern almost
included in B55
B*8202 B82 – B82 [23], B81 [19], 1 B45 [33], blank [67]b 3 B‘82’ 1 B56
B‘8201’ [11], B56
[5], B22 [3], B42 [3]a
B*8301 Undefined – – – B45 [100]b 1 – – Not assignede
NT, not tested; NN, neural network; HLA, human leukocyte antigen; WHO, World Health Organization; NMDP, National Marrow Donor Program.
a
Updated International Cell Exchange, UCLA.
b
Updated NMDP data. In some cases the information reported in previous dictionaries has changed. Cells have been excluded from this study in some cases because their HLA typing has changed.
c
WHO assignment based on dictionary data.
d
The allele has been identified but serology not informative.
e
Not assigned; see comment column for predictions >0.20.
f
If a primary specificity is provided by the NN, other specificities >0.4 are shown in the comments column.
g
Ref 13–16, 29–57, 62.
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 3 HLA-C alleles and their serologic designationsg
a
Cw*0102 Cw1 Cw1 Cw1 [55–75] 76 Cw1 [92] 260 Cw1 104 Training – Cw1
Cw*0103 Cw1 Cw1 – – Cw1 [100]b 1 – – Cw1
Cw*0104 Cw1 – – – – – – – Cw1
Cw*0105 Cw1 – – – – – – – Cw1
Cw*0106 Cw1 – – – – – – – Cw1
Cw*0107 Cw1/blank – – – Cw1 [100]b 1 – – Cw1 Cw blank, the HLA
club cell
exchange: nine
laboratories
performing
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
serology
Cw*0108 Cw1 – – – – – – – Cw1
Cw*0109 Cw1 Cw1 – – – – – – Cw1 Short Cw1
Cw*0110 Cw1 – – – – – – – Cw1
Cw*0111 Cw1 – – – – – – – Cw1
Cw*0112 Cw1 – – – – – – – Cw1
Cw*0113 Cw1 – – – – – – – Cw1
Cw*0114 Cw1 – – – – – – – Cw1
Cw*0115 Cw1 – – – – – – – Cw1
Cw*0116 Cw1 – – – – – – – Cw1
Cw*0117 Cw1 – – – – – – – Cw1
Cw*0118 Cw1 – – – – – – – Cw1
Cw*0119 Cw1 – – – – – – – Cw1
Cw*0202 Cw2 Cw2 Cw2 [62–76]a 27 Cw2 [91] 382 Cw2 67 Training – Cw2
Cw*0203 Cw2 – – – Cw2 [100]b 1 – – Cw2
Cw*0204 Cw2 – – – – – – – Cw2
Cw*0205 Cw2 – – – – – – – Cw2
Cw*0206 Cw2 – – – – – – – Cw2
Cw*0207 Cw2 – – – – – – – Cw2
Cw*0208 Cw2 Cw2 – – – – – – Cw2
Cw*0209 Cw2 – – – – – – – Cw2
Cw*0210 Cw2 Cw2 – – Cw2 [75]b 4 Cw2
Cw*0211 Cw2 – – – – – – – Cw2
Cw*0212 Cw2 – – – – – – – Cw2
Cw*0213 Cw2 – – – – – – – Cw2
Cw*0214 Cw2 – – – – – – – Cw2
Cw*0215 Cw2 – – – – – – – Cw2
Cw*0216 Cw2 – – – – – – – Cw2
Cw*0217 Cw2 – – – – – – – Cw2
HLA alleles and serologic types
143
Table 3 Continued
144
International Cell Exchange, UCLA NMDP IHWS13 data NN
[8–15]a
Cw*0304 Cw10 Cw10(w3) Cw3 [52–69], Cw9 62 Cw3 [92], Cw10 [3], 603 Cw10 51 Training – Cw3 Cw10
[0–11], Cw10 Cw9 [1]
[3–12]a
Cw*0305 Cw3 – Cw3 [48], Cw10 [7]a 1 Cw3 [83], blank [17]b 12 – – Cw10
Cw*0306 Cw10 Cw10(w3)c Cw3 [52], Cw10 [6] 1 Cw3 [75], blank [25]b 16 Cw10 1 Cw10 ihw13: short pattern
Cw*0307 Cw3 Cw3 – – Cw3 [100]b 1 – – Cw10
Cw*0308 Cw10 – – – – – – – Cw10
Cw*0309 Cw10 Cw3c Cw3 [44–59], Cw10 3 Cw3 [100]b 1 – – Cw10
[3–6]
Cw*0310 Cw3 Cw3 – – Cw3 [100]b 1 – – Cw10
Cw*0311 Cw9 Cw3 – – – – – – Cw9
Cw*0312 Cw9 – – – – – – – Cw9
Cw*0313 Cw9 – – – – – – – Cw9
Cw*0314 Cw10 – – – – – – – Cw10
Cw*0315 Undefined – – – – – – – Not assignedd NN: Cw3, Cw10
Cw*0316 Blank – – – – – – – Cw3 Cw3, w9, w10 sera
negative; NN:
Cw10
Cw*0317 Cw10 – – – – Cw10
Cw*0318 Cw9 – – – Cw3 [100]b 1 Cw9
Cw*0319 Cw3 Cw3 – – – – – – Cw10
Cw*0320N Not expressed Null – – – – – – NT
Cw*0321 Cw9 – – – – – – – Cw9
Cw*0322Q Undefined – – – – – – – Cw9 Not expected to be
expressed
Cw*0323 Cw10 – – – – – – – Cw10
Cw*0324 Cw10 Cw3 – – – – – – Cw10
Cw*0325 Cw10 – – – – – – – Cw10
Cw*0326 Cw10 Cw10(w3) – – – – – – Cw10
Cw*0327 Cw10 – – – – – – – Cw10
Cw*0328 Cw10 Cw10(w3) – – – – – – Cw10
Cw*0329 Cw10 – – – – – – – Cw10
Cw*0330 Cw9 – – – – – – – Cw9
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 3 Continued
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Cw*0341 Cw10 – – – – – – – Cw10
Cw*0401 Cw4 Cw4 Cw4 [54–76]a 107 Cw4 [98] 736 Cw4 114 Training – Cw4
Cw*0403 Cw4/Cw6 – Cw4 [16–33], Cw6 35 Blank [100]b 7 Cw4 11 Not assignedd NN: Cw4; Cw4/6
[7–26], C‘403’ variant; ihw13: Cw6
[3–8]a or blank, only Cw4
1 6 sera reactive
Cw*0404 Cw4 – – – Cw4 [75], blank [25]b 4 Blank 1 Cw4
Cw*0405 Cw4 – – – Cw4 [100]b 2 – – Cw4
Cw*0406 Cw4/Cw6 – Cw6 [27–33], Cw4 4 – – – – Not assignedd NN: Cw4
[20–25], C‘403’
[2–3]a
Cw*0407 Cw4 Cw4c – – Cw4 [100]b 1 Cw4 1 Cw4
be
Cw*0408 Cw4 – – – 1 – – Cw4
Cw*0409N Not expressed Null – 1 Blank [100]b 2 – – NT
Cw*0410 Cw4 Cw4 – – Cw4 [100]b 1 – – Cw4 Normal Cw4
Cw*0411 Undefined – – – – – – – Not assignedd NN: Cw4
Cw*0412 Cw4 – – – – – – – Cw4
Cw*0413 Cw4 – – – – – – – Cw4
Cw*0414 Cw4 – – – – – – – Cw4
Cw*0415 Cw4 – – – – – – – Cw4
Cw*0416 Cw4 – – – – – – – Cw4
Cw*0417 Cw4 – – – – – – – Cw4
Cw*0418 Cw4 – – – – – – – Cw4
Cw*0419 Cw4 – – – – – – – Cw4
Cw*0420 Cw4 Cw4 – – – – – – Cw4
Cw*0421 Cw4 – – – – – – – Cw4
Cw*0423 Cw4 – – – – – – – Cw4
Cw*0424 Cw4 – – – – – – – Cw4
Cw*0425 Cw4 – – – – – – – Cw4
HLA alleles and serologic types
145
Table 3 Continued
146
International Cell Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 3 Continued
Cw*0704 Cw7 Cw7 Cw7 [59–72] 14 Cw7 [64], blank [24] 54 Cw7 30 Cw7
Cw*0705 Cw7 Cw7c – – – – Cw7 2 Cw7
Cw*0706 Cw7 Cw7 Cw7 [62–76] 4 Cw7 [67], blank [33]b 3 – – Cw7
Cw*0707 Cw7 – – – Blank [100]b 1 – – Cw7
Cw*0708 Cw7 – – – Cw7 [100]b 1 – – Cw7
Cw*0709 Cw7 – – – Cw7 [100]b 1 – – Cw7
Cw*0710 Cw7 – – – Cw7 [100]b 1 – – Cw7
Cw*0711 Cw7 – – – – – – – Cw7
Cw*0712 Cw7 Cw7 – – – – – – Cw7
Cw*0713 Cw7 – – – – – – – Cw7
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Cw*0714 Cw7 Cw7 – – – – – – Cw7
Cw*0715 Cw7 – – – – – – – Cw7
Cw*0716 Cw7 Cw7 – – Blank [100]b 1 – – Cw7
Cw*0717 Cw7 – Cw7 [61%] allele 1 – – – – Cw7
typed outside
primary cell range
Cw*0718 Cw7 – Cw7 [73]a 1 Cw7 [67], blank [33]b 3 – – Cw7
Cw*0719 Cw7 – – – – – – – Cw7
Cw*0720 Cw7 – – – – – – – Cw7
Cw*0721 Cw7 – – – – – – – Cw7
Cw*0722 Cw7 – – – – – – – Cw7
Cw*0723 Cw7 – – – – – – – Cw7
Cw*0724 Cw7 – – – – – – – Cw7
Cw*0725 Cw7 – – – – – – – Cw7
Cw*0726 Cw7 – – – – – – – Cw7
be
Cw*0727 Cw7 – – – 1 – – Cw7
Cw*0728 Cw7 – – – – – – – Cw7
Cw*0729 Cw7 – – – – – – – Cw7
Cw*0730 Cw7 Cw7 – – – – – – Cw7
Cw*0731 Cw7 – – – – – – – Cw7
Cw*0732N Not expressed Null – – – – – – NT
Cw*0733N Not expressed Null – – – – – – NT
Cw*0734 Cw7 – – – – – – – Cw7
Cw*0735 Cw7 – – – – – – – Cw7
Cw*0736 Cw7 Cw7 – – – – – – Cw7
Cw*0737 Cw7 Cw7 – – – – – – Cw7
Cw*0738 Cw7 Cw7 – – – – – – Cw7
Cw*0739 Cw7 – – – – – – – Cw7
HLA alleles and serologic types
147
Table 3 Continued
148
International Cell Exchange, UCLA NMDP IHWS13 data NN
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 3 Continued
d
Cw*1210 Undefined – – – – – – – Not assigned
Cw*1211 Undefined – – – – – – – Not assignedd
Cw*1212 Undefined – – – – – – – Not assignedd
Cw*1213 Undefined – – – – – – – Not assignedd
Cw*1214 Cw7 – – – – – – – Cw7
Cw*1215 Undefined – – – – – – – Not assignedd
Cw*1216 Undefined – – – – – – – Not assignedd NN: Cw7
Cw*1217 Undefined – – – – – – – Not assignedd
Cw*1218 Undefined – – – – – – – Not assignedd NN: Cw7
Cw*1219 Undefined – – – – – – – Not assignedd
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Cw*1220 Undefined – – – – – – – Not assignedd
Cw*1221 Undefined – – – – – – – Not assignedd NN: Cw2, Cw5
Cw*1402 Cw1/blank – Blank, no Cw antigen 19a Blank [93] 93 Cw1 36 Cw1 ihw13: short Cw1
reported by more
than 5% of the
laboratories
Cw*1403 Cw1/blank – Blank, no Cw antigen 5a Blank [100]b 11 Cw1 10 Not assignedd ihw13: short Cw1;
reported by more NN: Cw1
than 5% of the
laboratories
Cw*1404 Undefined – – – Blank [100]b 1 – – Not assignedd NN: Cw4, Cw1
Cw*1405 Cw1 – – – Blank [100]b 1 – – Cw1
Cw*1406 Undefined – – – – – – – Not assignedd NN: Cw1
Cw*1407N Not expressed Null – – – – – – NT
Cw*1408 Cw1 – – – – – – – Cw1
Cw*1502 Undefined – Blank 31a Blank [90] 107 Blank 56 Not assignedd NN: Cw10, Cw3, Cw2
Cw*1503 Undefined – – – Blank [100]b 2 – – Not assignedd NN: Cw10, Cw3, Cw2
Cw*1504 Undefined – – – Blank [100]b 2 Blank 2 Not assignedd NN: Cw3, Cw2
Cw*1505 Undefined – Blanka 11a Blank [62], Cw7 [24], 29 Blank 5 Not assignedd NN: Cw10, Cw3,
Cw2 [10]b Cw2, Cw5
Cw*1506 Undefined – – – Blank [100]b 1 – – Not assignedd NN: Cw10, Cw3, Cw2
Cw*1507 Cw3 – – – – – – – Cw3f NN: Cw10
Cw*1508 Undefined – – – – – – – Not assignedd NN: Cw10, Cw3,
Cw2, Cw5
Cw*1509 Undefined – Blank 1 Blank [100]b 8 – – Not assignedd NN: Cw3, Cw2
Cw*1510 Undefined – – – – – – – Not assignedd
Cw*1511 Undefined – – – Blank [100]b 1 – – Not assignedd NN: Cw2, Cw3, Cw10
Cw*1512 Undefined – – – – – – – Not assignedd NN: Cw3, Cw9, Cw2
HLA alleles and serologic types
149
Table 3 Continued
150
International Cell Exchange, UCLA NMDP IHWS13 data NN
Cw*1513 Undefined – – – Blank [100]b 1 – – Not assignedd NN: Cw10, Cw3, Cw2
Cw*1514 Undefined – – – – – – – Not assignedd
Cw*1515 Undefined – – – – – – – Not assignedd NN: Cw10, Cw3, Cw2
Cw*1516 Undefined – – – – – – – Not assignedd NN: Cw10, Cw3
HLA alleles and serologic types
NT, not tested; NN, neural network; HLA, human leukocyte antigen; WHO, World Health Organization; NMDP, National Marrow Donor Program.
a
Updated International Cell Exchange, UCLA.
b
Updated NMDP data. In some cases, the information reported in previous dictionaries has changed. Cells have been excluded from this study in some cases because their HLA typing has changed.
c
WHO assignment based on dictionary data.
d
Not assigned; see comment column for predictions >0.20.
e
The allele has been identified but serology not informative.
f
If a primary specificity is provided by the NN, other specificities >0.4 are shown in the comments column.
g
Ref 14, 58, 59.
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 4 HLA-DRB1 alleles and their serologic designations
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
DRB1*0101 DR1 DR1 DR1 [95–100]a 21 DR1 [97] 6317 Training – DR1
R. Holdsworth et al.
DRB1*0102 DR1 DR1 DR1 [86–95] 2 DR1 [95] 2035 Training – DR1
DRB1*0103 DR103/DR1 DR103 DR103 [75–80], 5 DR1 [56], DR103 1186 Training – DR1
DR1 [9–17]a [12], blank [18] DR103
DRB1*0104 DR1 DR1 – – – – DR1
DRB1*0105 DR1 – – – DR1 [100]b 2 DR1
DRB1*0106 DR1 – – – – – DR1
DRB1*0107 DR1 DR1 – – – – DR1
DRB1*0108 DR1 – – – – – DR1
DRB1*0109 DR1 DR1 – – – – DR1
DRB1*0110 DR1 – – – – – DR1
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
DRB1*0111 DR1 – – – – – DR1
DRB1*0112 DR1 – – – – – DR1
DRB1*0113 DR1 DR1 – – – – Not assignedc NN: DR1
DRB1*0114 DR1 – – – – – DR1
DRB1*0115 DR1 – – – – – DR1
DRB1*0116 DR1 – – – – – DR1
DRB1*0301 DR17 DR17(3) DR17 [33–70], 36 DR17 [64], DR3 9698 Training – DR3
DR3 [20–50], [33] DR17
DR18 [0–11]a
DRB1*0302 DR18 DR18(3) DR18 [62–67], 10 DR18 [66], DR3 317 Training – DR3
DR3 [27–35] [24], DR17 [3] DR18
DRB1*0303 DR18 DR18(3) – – DR18 [50], DR17 4 DR18
[50]b
DRB1*0304 DR17 DR17(3) DR17 [50], DR3 3 DR3 [57], DR17 7 DR17
[44–50]a [29]b
DRB1*0305 DR3 DR3 – – – – DR17
DRB1*0306 DR3 DR3 – – – – DR17
DRB1*0307 DR3 DR3d – – DR3 [100]b 1 DR17
DRB1*0308 DR3 – – – – – DR17
DRB1*0309 DR3 – – – – – DR17
DRB1*0310 DR3 DR17(3)d – – DR3 [100]b 1 DR17
DRB1*0311 DR3 DR17(3)d – – DR3 [100]b 1 DR17
DRB1*0312 DR3 DR3 – – – – DR17
DRB1*0313 DR3 – – – – – DR17
DRB1*0314 DR3 DR3 – – – – DR17
DRB1*0315 DR17 DR3 DR3 [38–40], 2 – – DR17
DR17 [20–25],
DR18 [0–10]a
DRB1*0316 DR3 – – – – – DR17
HLA alleles and serologic types
151
Table 4 Continued
152
International Cell Exchange, UCLA NMDP NN
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 4 Continued
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
DRB1*0432 DR4 DR4d DR4 [94–100]a 2 – – DR4
DRB1*0433 DR4 – – – DR4 [100]b 1 DR4
DRB1*0434 DR4 – – – – – DR4
DRB1*0435 DR4 – – – DR4 [100]b 1 DR4
DRB1*0436 DR4 – – – – – DR4
DRB1*0437 DR4 – – – – – DR4
DRB1*0438 DR4 – – – – – DR4
DRB1*0439 DR4 – – – – – DR4
DRB1*0440 DR4 – – – – – DR4
DRB1*0441 DR4 – – – – – DR4
DRB1*0442 DR4 DR4 – – – – DR4
DRB1*0443 DR4 – – – – – DR4
DRB1*0444 DR4 – – – – – DR4
DRB1*0445 DR4 – – – – – DR4
DRB1*0446 DR4 – – – – – DR4
DRB1*0447 DR4 – – – – – DR4
DRB1*0448 DR4 – – – – – DR4
DRB1*0449 DR4 – – – – – DR4
DRB1*0450 DR4 – – – – – DR4
DRB1*0451 DR4 – – – – – DR4
DRB1*0452 DR4 – – – – – DR4
DRB1*0453 DR4 – – – – – DR4
DRB1*0454 DR4 – – – – – DR4
DRB1*0455 DR4 – – – – – DR4
DRB1*0456 DR4 – – – – – DR4
DRB1*0457 DR4 – – – – – DR4
DRB1*0458 DR4 – – – – – DR4
DRB1*0459 DR4 – – – – – DR4
HLA alleles and serologic types
153
Table 4 Continued
154
International Cell Exchange, UCLA NMDP NN
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
DRB1*0701 DR7 DR7 DR7 [93–100]a 43 DR7 [99] 7390 Training – DR7
DRB1*0703 DR7 DR7 – – – – DR7
DRB1*0704 DR7 DR7 DR7 [100] 2 – – DR7
DRB1*0705 DR7 – – – – – DR7
DRB1*0706 DR7 – – – – – DR7
DRB1*0707 DR7 – – – – – DR7
DRB1*0708 DR7 – – – – – DR7
DRB1*0709 DR7 DR7 – – – – DR7
DRB1*0710N Not expressed Null – – – – NT
DRB1*0711 DR7 – – – – – DR7
DRB1*0712 DR7 – – – – – DR7
DRB1*0713 DR7 – – – – – DR7
DRB1*0714 DR7 – – – – – DR7
DRB1*0801 DR8 DR8 DR8 [91–100]a 7 DR8 [95] 1076 Training – DR8
DRB1*0802 DR8 DR8 DR8 [100]a 4 DR8 [96] 265 Training – DR8
DRB1*0803 DR8 DR8 DR8 [96–100] 12 DR8 [88], DR12 [3] 230 Training – DR8
DRB1*0804 DR8 DR8 DR8 [88–100]a 9 DR8 [93] 186 Training – DR8
DRB1*0805 DR8 DR8 – – DR8 [83]b 6 DR8
DRB1*0806 DR8 DR8 DR8 [96–100] 4 DR8 [95]b 21 DR8
DRB1*0807 DR8 DR8 DR8 [89] 1 DR8 [100]b 3 DR8
DRB1*0808 DR8 – – – – – DR8
DRB1*0809 DR8 DR8 – – DR8 [100]b 2 DR8 DR8 variant
DRB1*0810 DR8 DR8 DR8 [94–100]a 2 DR8 [67], DR12 9 DR8
[22]b
DRB1*0811 DR8 DR8 DR8 [89–94]a 2 DR8 [100]b 10 DR8
DRB1*0812 DR8 DR8 – – – – DR8
DRB1*0813 DR8 DR8 – – – – DR8
DRB1*0814 DR8 DR8 DR8 [74–78]a 2 – – DR8
DRB1*0815 DR8 – – – – – DR8
DRB1*0816 DR8 DR8 DR8 [85]a 1 – – DR8
DRB1*0817 DR8 DR8 – – – – DR8
DRB1*0818 DR8 DR8 – – DR8 [100]b 2 DR8
DRB1*0819 DR8 – – – – – DR8
DRB1*0820 undefined – – – – – Not assignedc NN: DR8
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 4 Continued
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
DRB1*0832 Undefined – – – – – Not assignedc NN: DR8, DR12
DRB1*0901 DR9 DR9 DR9 [89–100] 19 DR9 [95] 1058 Training – DR9
DRB1*0902 DR9 – – – – – DR9
DRB1*0903 DR9 – – – – – DR9
DRB1*0904 DR9 – – – – – DR9
DRB1*0905 DR9 DR9 – – – – DR9
DRB1*0906 DR9 – – – – – DR9
DRB1*1001 DR10 DR10 DR10 [87–100]a 14 DR10 [90], DR1 894 Training – DR10
[4], blank [2]
DRB1*1101 DR11 DR11(5) DR11 [88–100]a 15 DR11 [92], DR5 [5] 3474 Training – DR11
DRB1*1102 DR11 DR11(5) DR11 [89–100] 6 DR11 [89], DR5 [3] 430 Training – DR11
DRB1*1103 DR11 DR11(5) DR11 [84–100] 2 DR11 [89], DR5 [4] 397 Training – DR11
DRB1*1104 DR11 DR11(5) DR11 [87–100]a 13 DR11 [87], DR5 [4] 2119 Training – DR11
DRB1*1105 DR11 DR11(5) DR11 [90–100]a 2 DR11 [100]b 3 DR11
DRB1*1106 DR11 DR11(5) – – DR5 [79], DR11 14 DR11
[21]b
DRB1*1107 DR11 DR11(5)d – – DR11 [100]b 3 Not assignedc DR11x3; NN:
DR17, DR3, DR11
be
DRB1*1108 DR11 DR11(5) DR11 [91–100]a 3 1 DR11
DRB1*1109 DR11 DR11(5) DR11 [100] 1 DR11 [75], DR5 4 Training – DR11
[25]b
DRB1*1110 DR11 – – – DR11 [100]b 2 DR11
DRB1*1111 DR11 DR11(5) DR11 [87–90], 3 DR11 [90], DR5 10 DR11 DR11x13
DR13 [7–8], [10]b
DR5 [4–5]
DRB1*1112 DR11 – – – DR11 [100]b 5 DR11
DRB1*1113 DR11 DR11(5) DR11 [93]a 2 DR11 [86]b 7 DR11 DR11x14
DRB1*1114 DR11 DR11(5) DR11 [94–100]a 3 DR11 [100]b 2 DR11
HLA alleles and serologic types
155
Table 4 Continued
156
International Cell Exchange, UCLA NMDP NN
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
be
DRB1*1118 DR11 – – – 1 DR11
be
DRB1*1119 DR11 DR11(5) DR11 [100] 4 1 DR11
DRB1*1120 DR11 DR11(5) – – – – DR11 DR11x13
DRB1*1121 DR11 DR11(5) DR11 [88–97], 2 – – DR11
DR13 [12]a
DRB1*1122 Undefined – – – – – Not assignedc NN: DR11
DRB1*1123 DR11 DR11(5) – – – – DR11
DRB1*1124 DR11 – – – – – DR11
DRB1*1125 DR11 DR11(5) – – – – DR11
DRB1*1126 DR11 DR11(5) – – – – DR11
DRB1*1127 DR11 DR11(5) – – – – DR11
DRB1*1128 DR11 – – – – – DR11
DRB1*1129 DR11 DR11(5) DR11 [100] 2 – – DR11
DRB1*1130 DR11 – – – – – DR11
DRB1*1131 DR11 – – – – – DR11
DRB1*1132 DR11 – – – – – DR11
DRB1*1133 DR11 – – – – – DR11
DRB1*1134 DR11 – – – – – DR11
DRB1*1135 DR11 – – – – – DR11
DRB1*1136 DR11 – – – – – DR11
DRB1*1137 DR11 DR11(5) – – – – DR11
DRB1*1138 DR11 – – – – – DR11
DRB1*1139 DR11 – – – – – DR11
DRB1*1140 DR11 – – – – – DR11
DRB1*1141 DR11 – – – – – DR11
DRB1*1142 DR11 – – – – – DR11
DRB1*1143 DR11 – – – – – DR11
DRB1*1144 DR11 – – – – – DR11
DRB1*1145 DR11 – – – – – DR11
DRB1*1146 DR11 – – – – – DR11
DRB1*1147 DR11 – – – – – DR11
DRB1*1148 DR11 – – – – – DR11
DRB1*1149 DR11 – – – – – DR11
DRB1*1150 DR11 – – – – – DR11
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 4 Continued
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
DRB1*1162 DR11 – – – – – DR11
DRB1*1201 DR12 DR12(5) DR12 [85–100], 9 DR12 [83], DR5 893 Training – DR12
DR13 [5–12] [4], DR8 [2],
DR11 [2]
DRB1*1202 DR12 DR12(5) DR12 [91–100] 17 DR12 [89] 162 Training – DR12
DRB1*1203 DR12 DR12(5) – – DR12 [100]b 4 DR12
DRB1*1204 DR12 – – – – – DR12 DR12x11
DRB1*1205 DR12 DR12(5) – – – – DR12
DRB1*1206 DR12 DR12(5) – – DR12 [100]b 3 DR12
DRB1*1207 DR12 – – – – – DR12
DRB1*1208 DR12 – – – – – DR12
DRB1*1209 DR12 – – – – – DR12
DRB1*1210 DR12 – – – – – DR12
DRB1*1211 DR12 – – – – – DR12
DRB1*1212 DR12 – – – – – DR12
DRB1*1213 DR12 – – – – – DR12
DRB1*1214 DR12 – – – – – DR12
DRB1*1215 DR12 – – – – – DR12
DRB1*1301 DR13 DR13(6) DR13 [90–100], 17 DR13 [81], DR6 3788 Training – DR6 DR13
DR6 [0–7]a [14], DR14 [1]
DRB1*1302 DR13 DR13(6) DR13 [81–97], 17 DR13 [74], DR6 3081 Training – DR6 DR13
DR6 [7–11]a [17], DR14 [2]
DRB1*1303 DR13 DR13(6) DR13 [50–93], 11 DR13 [69], DR6 948 Training – DR6 DR13
DR6 [4–21], [10], DR12 [3],
DR‘1303’ DR11 [3], DR5
[0–11], DR14 [2], DR14 [2]
[0–17], DR3
[0–8]
HLA alleles and serologic types
157
Table 4 Continued
158
International Cell Exchange, UCLA NMDP NN
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 4 Continued
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
DRB1*1332 DR13 – – – – – DR13
DRB1*1333 DR13 – – – – – DR13
DRB1*1334 DR13 – – – – – DR13
DRB1*1335 DR13 – – – – – DR13
DRB1*1336 DR13 DR13(6) DR13 [91–100], 3 DR6 [100]b 1 DR13
DR6 [0–5],
DR14 [0–4]a
DRB1*1337 DR13 – – – – – DR13
DRB1*1338 DR13 – – – – – DR13
DRB1*1339 DR13 – – – – – DR13
DRB1*1340 DR13 – – – – – DR13
DRB1*1341 DR13 – – – – – DR13
DRB1*1342 DR6 DR13(6) – – – – DR6
DRB1*1343 DR13 – – – – – DR13
DRB1*1344 Undefined – – – – – Not assignedc NN: DR11
DRB1*1345 DR13 – – – – – DR13
DRB1*1346 DR11 – – – – – DR11
DRB1*1347 Undefined – – – – – Not assignedc NN: DR8
DRB1*1348 DR13 – – – – – DR13
DRB1*1349 DR6 – – – – – DR6
DRB1*1350 DR11 – – – – – DR11
DRB1*1351 DR13 – – – – – DR13
DRB1*1352 DR13 DR13(6) – – – – DR13
DRB1*1353 DR13 – – – – – DR13
DRB1*1354 DR14 DR14(6) – – – – Not assignedc NN: DR11
DRB1*1355 Undefined – – – – – Not assignedc NN: DR8, DR6
DRB1*1356 DR6 – – – – – DR6 NN: DR13
DRB1*1357 DR13 DR13(6) – – – – DR13
HLA alleles and serologic types
159
Table 4 Continued
160
International Cell Exchange, UCLA NMDP NN
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 4 Continued
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
DRB1*1406 DR14 DR14(6) DR13 [28], DR14 1 DR14 [37], DR13 117 Training – DR6 DR14
R. Holdsworth et al.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
[12], DR11 [12], DR14
DR‘14x11’ [9]
DRB1*1412 DR14 DR14(6) – – – – DR14 NN: DR6
DRB1*1413 DR14 DR14(6) DR14 [59–86], 3 DR6 [100]b 1 DR14
DR6 [4–17],
DR13 [0–10]
DRB1*1414 DR14 DR14(6) DR14 [88–89], 2 – – DR14
DR13 [0–5]
DRB1*1415 DR8 DR8 DR8 [50], DR14 1 DR8 [100]b 1 DR8 DR8 1 DR52
[26], DR13 [8]
DRB1*1416 DR6 DR6 – – DR14 [100]b 1 DR13 DR14x13
DRB1*1417 DR6 DR6 – – DR13 [100]b 1 DR6 DR14x13; DR13
weak, DR14
negative
DRB1*1418 DR14 DR6 – – DR14 [100]b 1 DR14
DRB1*1419 DR14 DR14(6) – – – – DR14
DRB1*1420 DR14 DR14(6) – – Blank [100]b 1 DR14
DRB1*1421 DR14 DR14(6) DR14 [57–84], 3 DR6 [100]b 1 DR6 Also typed as
DR13 [8–29], DR13
DR6 [4–14],
DR17 [0–6]a
DRB1*1422 DR14 DR14(6)d – – – – DR14
DRB1*1423 DR14 – – – DR14 [100]b 1 DR14
DRB1*1424 DR14 – – – – – DR14
DRB1*1425 DR6 – – – – – DR6
DRB1*1426 DR14 DR14(6) – – – – DR14
DRB1*1427 DR14 DR14(6) – – – – DR6 NN: DR14
DRB1*1428 DR14 – – – – – DR14
HLA alleles and serologic types
161
Table 4 Continued
162
International Cell Exchange, UCLA NMDP NN
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 4 Continued
HLA allele Expert assigned WHO assigned Assigned type [%] Cells tested Assigned type [%] Cells tested Assigned type >0.55 Comments
DRB1*1501 DR15 DR15(2) DR15 [75–90], 31 DR15 [76], DR2 6428 Training – DR2 DR15
DR2 [0–19], [23]
DR16 [0–13]a
DRB1*1502 DR15 DR15(2) DR15 [82–100], 17 DR15 [77], DR2 676 Training – DR2 DR15
DR2 [0–14]a [16]
DRB1*1503 DR15 DR15(2) DR15 [81–94], 8 DR15 [81], DR2 286 Training – DR2 DR15
DR2 [3–13], [13]
DR16 [0–6]a
DRB1*1504 DR15 DR15(2)d DR15 [76–91], 4 DR15 [100]b 1 DR15
DR2 [0–18],
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
DR16 [0–6]a
DRB1*1505 DR15 DR15(2) – – DR15 [100]b 1 DR15
DRB1*1506 DR15 DR15(2) – – DR15 [100]b 2 DR15
DRB1*1507 DR15 DR15(2)d DR15 [82–91], 2 – – DR15
DR2 [5–9],
DR16 [0–9]a
DRB1*1508 DR15 DR2 – – – – DR15
DRB1*1509 DR15 – – – – – DR15
DRB1*1510 DR2 – – – – – DR2 NN: DR15
DRB1*1511 DR15 – – – – – DR15
DRB1*1512 DR15 – – – – – DR15
DRB1*1513 DR2 – – – – – DR2 NN: DR15, DR16
DRB1*1514 DR15 – – – DR15 [100]b 1 DR15
DRB1*1515 DR15 – – – – – DR15
DRB1*1516 DR15 – – – – – DR15
DRB1*1517N Not expressed Null – – – – NT
DRB1*1518 DR15 – – – – – DR15
DRB1*1519 DR15 – – – – – DR15
DRB1*1520 DR15 – – – – – DR15
DRB1*1521 DR2 – – – – – DR2f NN: DR15, DR16
DRB1*1522 DR15 – – – – – DR15
DRB1*1601 DR16 DR16(2) DR16 [31], DR15 1 DR16 [41], DR2 703 Training – DR2 DR16
[38], DR2 [31] [29], DR15 [19]
DRB1*1602 DR16 DR16(2) DR16 [56–82], 13 DR16 [47], DR2 239 Training – DR2 DR16
DR2 [12–28], [30], DR15 [16]
DR15 [6–22]a
DRB1*1603 DR16 DR2 – – – – DR16
HLA alleles and serologic types
163
HLA alleles and serologic types R. Holdsworth et al.
Updated NMDP data. In some cases, the information reported in previous dictionaries has changed. Cells have been excluded from this study in some cases because their HLA typing has changed.
not have associated serologic typing. In some cases, the
Comments
number of cells tested is less than the number in the last
dictionary. In these cases, the typing assignment may have
changed or further data suggest that the typing result was
not informative.
Assigned type >0.55
Neural network
An artificial NN was used to predict serologic assignments
for alleles lacking this information and to support serologic
assignments from other sources (7). The same set of alleles
DR16
DR16
DR16
DR16
DR16
DR16
DR16
1
–
–
–
–
–
DR16 [100]b
If a primary specificity is provided by the NN, other specificities >0.4 are shown in the comments column.
–
–
–
–
–
–
DR2 [9–31]a
DR16(2)
–
–
nmdp.org/neuralnetwork2007.
The use of a NN to predict the serologic assignments of
Expert assigned
DR16
DR16
DR16
DR16
DR16
DR16
Tables 3 and 6.
Table 4 Continued
DRB1*1605
DRB1*1607
DRB1*1608
DRB1*1609
DRB1*1610
DRB1*1611
e
a
164 ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
Table 5 HLA-DRB3, DRB4, DRB5 alleles and their serologic designations
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
DRB3*0111 Undefined – DRB4*0106 Undefined – – –
DRB3*0201 DR52 DR52 DR52 [97–100]a 3 DRB4*0107 Undefined –
DRB3*0202 DR52 DR52 DR52 [90–100] 126 DRB4*0201N Not expressed Null – –
DRB3*0203 DR52 DR52 DR52 [100] 1 DRB4*0301N Not expressed Null Refer to comments 1 DR53 (69) false-positive
assignments
DRB3*0204 Undefined – – – DRB5*0101 DR51 DR51 DR51 [82–100]a 41
DRB3*0205 Undefined – – – DRB5*0102 DR51 DR51 DR51 [86–100]a 10
DRB3*0206 DR52 – DR52 [91]a 1 DRB5*0103 Undefined – – –
DRB3*0207 DR52 DR52 – – DRB5*0104 Undefined – – –
DRB3*0208 DR52 DR52 – – DRB5*0105 Undefined – – –
DRB3*0209 DR52 DR52 – – DRB5*0106 Undefined – – –
DRB3*0210 DR52 DR52 – – DRB5*0107 DR51 DR51 – –
DRB3*0211 DR52 DR52 – – DRB5*0108N Not expressed Null Refer to commentsa 2 DR51 (43–60), false-
positive assignments
DRB3*0212 Undefined – – – DRB5*0109 Undefined – – –
DRB3*0213 Undefined – – – DRB5*0110N Not expressed Null Refer to commentsa 1 DR51 (55), false-positive
assignments
DRB3*0214 Undefined – – – DRB5*0111 Undefined –
DRB3*0215 Undefined – – – DRB5*0112 Undefined –
DRB3*0216 Undefined – – – DRB5*0113 Undefined –
DRB3*0217 Undefined – – – DRB5*0202 DR51 DR51 DR51 [86–100]a 15
DRB3*0218 Undefined – – – DRB5*0203 Undefined – – –
DRB3*0219 Undefined – – – DRB5*0204 Undefined – – –
DRB3*0220 Undefined – – – DRB5*0205 Undefined – – –
DRB3*0221 Undefined – – –
NT, not tested; NN, neural network; HLA, human leukocyte antigen; WHO, World Health Organization; NMDP, National Marrow Donor Program.
a
Updated International Cell Exchange, UCLA.
HLA alleles and serologic types
165
HLA alleles and serologic types R. Holdsworth et al.
166 ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
R. Holdsworth et al. HLA alleles and serologic types
Table 6 Continued
DQB1*0602 DQ6 DQ6(1) DQ1 [38–73], DQ6 22 DQ6 [67], DQ1 5151 Training – DQ1 DQ6
[18–64], DQ5 [30], DQ5 [1]
[0–12]a
DQB1*0603 DQ6 DQ6(1) DQ1 [31–64], DQ6 18 DQ6 [62], DQ1 2807 DQ6
[22–63], DQ5 [23], DQ5 [2]
[0–10]a
DQB1*0604 DQ6 DQ6(1) DQ1 [40–52], DQ6 3 DQ6 [59], DQ1 1592 DQ6
[40–44], DQ5 [27], DQ5 [2]
[0–20]a
DQB1*0605 DQ6 DQ6(1) – – DQ6 [76], DQ1 358 DQ6
[13]
DQB1*0606 DQ5 – – – DQ5 [100]b 1 DQ5
DQB1*0607 DQ6 – – – DQ1 [75], DQ6 4 DQ6
[25]b
DQB1*0608 DQ6 DQ6(1)c – – DQ6 [50], DQ1 6 DQ6 DQ6
[25], DQ5 [25]b
DQB1*0609 DQ6 DQ6(1) DQ6 [38–67], DQ1 6 DQ6 [48], DQ1 149 DQ6
[27–44], DQ5 [32], DQ5 [3]
[0–6]a
DQB1*0610 DQ1 – – – DQ1 [100]b 1 DQ6
DQB1*0611 DQ1 DQ1 – – – – DQ6
DQB1*0612 DQ1 DQ1 – – – – DQ6
be
DQB1*0613 DQ6 – – – 1 DQ6
DQB1*0614 DQ6 DQ6(1) – – – – DQ6
DQB1*0615 DQ6 – – – – – DQ6
DQB1*0616 DQ6 – DQ6 [33–56], DQ1 2 – – DQ6
[32–56], DQ5
[6–11]a
be
DQB1*0617 DQ6 – – – 1 DQ6
DQB1*0618 DQ6 – – – – – DQ6
DQB1*0619 DQ6 – – – – – DQ6
DQB1*0620 DQ6 – – – – – DQ6
DQB1*0621 DQ6 – – – – – DQ6
DQB1*0622 DQ6 – – – – – DQ6
DQB1*0623 DQ6 – – – – – DQ6
DQB1*0624 DQ6 – – – – – DQ6
DQB1*0625 DQ6 DQ6(1) – – – – DQ6
DQB1*0626N Not expressed Null – – – – NT
DQB1*0627 DQ6 – – – – – DQ6
DQB1*0628 DQ6 – – – – – DQ6
DQB1*0629 DQ6 – – – – – DQ6
DQB1*0630 DQ6 – – – – – DQ6
DQB1*0631 DQ6 – – – – – DQ6
DQB1*0632 DQ6 – – – – – DQ6
DQB1*0633 DQ6 – – – – – DQ6
NT, not tested; NN, neural network; HLA, human leukocyte antigen; WHO, World Health Organization; NMDP, National Marrow Donor Program.
a
Updated International Cell Exchange, UCLA.
b
Updated NMDP data. In some cases, the information reported in previous dictionaries has changed. Cells have been excluded from this study in some
cases because their HLA typing has changed.
c
WHO assignment based on dictionary data.
d
If a primary specificity is provided by the NN, other specificities >0.4 are shown in the comments column.
e
The allele has been identified but serology not informative.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170 167
HLA alleles and serologic types R. Holdsworth et al.
tested with a common set of well-characterized reagents Some alleles in the tables are listed with more than one
including mainly monoclonal antibodies (12) and supple- common serological assignment. This indicates that the
mentary allosera. Tables 1–3 show the number of panel serological pattern is not clear, for example B*4416 has both
cells for each allele included in the analysis, the assigned B47 and B44 reactivity. The ‘Comments’ section may
specificity and, where appropriate, comments on the sero- provide further information for serological reactivity in
logical expression of that allele, as reported by the 13th some cases. In addition, many laboratories are not able to
IHWS serology and HLA phenotype component (8, 9). identify many of the WHO-designated HLA specificities.
These data have not been updated from the 2004 edition of The International Cell Exchange, UCLA data show that
the HLA data dictionary. some of the newer specificities are rarely used but are often
designated by their antigen equivalents, for example A2
Information obtained from other sources instead of A203. Although subsequent cell exchanges do
improve the detection rate, these assignments remain
Data on the serological expression of new alleles have been difficult. It is useful to refer to the percentage recogni-
submitted from HLA laboratories. However, because many tion information when selecting alternative antigens for
laboratories no longer perform serological typing or use alternative searches.
commercial monoclonal reagents, there are only a small
number of alleles that have been tested in this way. In this
Searchable links between alleles and serologic
edition of the dictionary, only 23 HLA class I alleles have
assignments
been submitted with serological information. The ‘Com-
ments’ column in the tables refers to information from A searchable form of the dictionary is available through the
publications (listed at end of document) and other sources IMGT/HLA database (5) at http://www.ebi.ac.uk/imgt/
that describe serologic expression of new alleles. It must be hla/. This information can then be used by HSC registries to
noted, however, that some of these data are based on small routinely update their matching algorithms and to support
sample numbers tested by a single laboratory. other search and matching activities.
168 ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170
R. Holdsworth et al. HLA alleles and serologic types
defined HLA-A, -B, -C, -DR and -DQ antigens. Tissue 20. Day S, Rawson J, Evans A, Dunn P. Identification and
Antigens 2005: 65: 1–55. characterization of a new HLA allele, A*0262 (BSHI abstract).
5. Robinson J, Malik A, Parham P, Bodmer JG, Marsh SGE. Eur J Immunogen 2003: 30: 305–23 (p315).
IMGT/HLA database – sequence database for the human 21. Anholts JDH, Drabbels J, Verduijn W, Oudshoorn M,
major histocompatibility complex. Tissue Antigens 2000: Schreuder GMTh. Five newly identified HLA alleles: A*0310,
55: 280–7. A*2907, B*4435, Cw*0206, Cw*0506, and confirmation of
6. Marsh SGE, Albert ED, Bodmer WF et al. Nomenclature A*3106, B*3924, Cw*0314, DRB1*0322 and DRB1*1433
for factors of the HLA system, 2004. Tissue Antigens 2005: alleles. Tissue Antigens 2004: 63: 80–4.
65: 301–68. 22. Pyo C-W, Choi H-B, Han H, Hong Y-S, Kim T-G.
7. Maiers M, Schreuder GMT, Lau M et al. Use of a neural Identification of HLA-A*11 variant (A*1107) in the Korean
network to assign serologic specificities to HLA-A, -B and population. Tissue Antigens 2001: 58: 190–2.
-DRB1 allelic products. Tissue Antigens 2003: 62: 21–47. 23. Palou E, Santos M, Gil J, Campos E, Nogues N, Ribera A.
8. Schreuder GMT, Holdsworth R, Tanaka H et al. The serologic Identification and sequence characterization of a novel
specificity of HLA-A, -B and -C alleles defined with reagents of HLA-A11 serological variant (HLA-A*1108). Tissue Antigens
the 13th International Histocompatibility Workshop. In: 2001: 57: 543–5.
Hansen JA, Dupont B, eds. HLA2002: Immunobiology of the 24. Garino E, Belvedere M, Berrino M et al. New HLA-A*11
Human MHC. Proceedings of the 13th International allele, A*1112, identified by sequence-based typing. Tissue
Histocompatibility Workshop and Congress, Vol. I and II. Antigens 2002: 60: 84–7.
Seattle: IHWG Press, 2006. 25. Takahashi D, Miyazaki T, Araseki M et al. Identification of
9. Fernandez-Vina MA, Yunis EJ. Summary report of the a novel allele HLA-A*1113 in a Japanese donor. Tissue
serology-allele phenotype component of the 13th International Antigens 2004: 64: 81–3.
Histocompatibility Workshop. In: Hansen JA, Dupont B, eds. 26. Wu G-G, Cheng L-H, Li Z et al. Identification of a new HLA
HLA 2002: Immunobiology of the Human MHC. Proceedings allele, A*1114 in a Chinese family. Tissue Antigens 2003:
of the 13th International Histocompatibility Workshop and 61: 253–5.
Congress, Vol. I and II. Seattle: IHWG Press, 2006. 27. Street J, Hammond L, Downing J, Thompson J, Darke C.
10. Marsh SGE, Albert ED, Bodmer WF et al. Nomenclature Observations on the HLA-A2403 specificity. Tissue Antigens
for factors of the HLA system, 2002. Hum Immunol 2002: 2003: 61: 330–3.
63: 1213–68. 28. Voorter CEM, Hepkema BG, Lems SPM, van den
11. Marsh SGE, Bodmer JG, Albert ED et al. Nomenclature Berg-Loonen EM. Molecular and serological identification
for factors of the HLA system, 2000. Tissue Antigens 2001: of the HLA-A*3404 allele. Tissue Antigens 2002:
57: 236–83. 60: 328–30.
12. Maiers M, Schreuder GMT, Yunis EJ, Fernandez-Vina MA. 29. Herbut B, Woodman R, Kowalick L, Malkki M, Petersdorf
A computational approach to serologic epitope mapping. In: EW, McKenna R. Identification of a novel HLA-B*07 allele –
Hansen JA, Dupont B, eds. HLA 2002: Immunobiology of the HLA-B*0726. Tissue Antigens 2002: 59: 60–2.
Human MHC. Proceedings of the 13th International 30. Longhi E, Frison S, Poli F et al. Identification of two new
Histocompatibility Workshop and Congress, Vol. I and II. HLA-B alleles, HLA-B*0732 and HLS-B*5809, by
Seattle: IHWG Press, 2006 sequence-based typing. Tissue Antigens 2004: 63: 273–8.
13. Street J, Downing J, Hammond L, Thompson J, Darke C. 31. Longhi E, Frison S, Espaolas de Arias A et al.
Immunogenetics of two new HLA alleles: A*0108 and B*4031. Characterization of two new HLA-B alleles by sequence-based
Tissue Antigens 2003: 61: 322–4. typing: HLA-B*0817 and B*1311. Tissue Antigens 2003:
14. Street J, Guttridge MG, Thompson J, Darke C. Genetics, 62: 66–71.
serology and sequences of six low frequency HLA-class I 32. Hemmatpour S, Gupta A, Dunn PPJ, Sinnot PJ. The allele
alleles (BSHI abstract). Eur J Immunogen 2001: 28: 467–503 B*1547 is serologically equivalent to the HLA-B48 antigen
(p502). (BSHI abstract). Eur J Immunogen 2003: 30: 305–23 (p323).
15. Gutierrez M, Araujo HA, Stoddard JF et al. Serological 33. Kervaire B, Tiercy J-M. Additional diversity within the B70
assignment of reported novel HLA-A and -B alleles (ASHI serotype: identification of B*1580 in a Caucasoid blood donor.
abstract). Hum Immunol 2002: 63: S40. Tissue Antigens 2004: 63: 270–2.
16. Street J, Hammond L, Thompson J, Darke C. Serological 34. Street J, Hammond L, Downing J, Thompson J, Rees TJ,
characterisation of the products of nine rare HLA class I alleles Darke C. A further example of HLA-B*2712 (BSHI abstract).
(abstract BSHI). Eur J Immunogen 2002: 29: 351–70 (p355). Eur J Immunogen 2002: 29: 351–70 (p358).
17. Yang KL, Gao X, Lin PY. Recognition of HLA-A*0248 in 35. Voorter CEM, Swelsen WTN, van den Berg-Loonen EM.
a Chinese donor. Eur J Immunogen 2003: 30: 185–6. B*27 in molecular diagnostics: impact of new alleles and
18. Voorter CEM, Gervais T, van den Berg-Loonen EM. polymorphism outside exons 2 and 3. Tissue Antigens 2002:
Identification of HLA-A*0249 and confirmation of A*2615. 60: 25–35.
Tissue Antigens 2002: 60: 529–33. 36. Tamouza R, Mansour I, Bouguacha N et al. A new
19. Czachurski D, Rausch M, Scherer S, Opelz G, Mytilineos J. HLA-B*27 allele (B*2719) identified in a Lebanese patient
Characterization of a new HLA-A allele, A*0256, identified in affected with ankylosing spondylitis. Tissue Antigens 2001:
a Caucasian individual. Tissue Antigens 2002: 60: 180–3. 58: 30–3.
ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170 169
HLA alleles and serologic types R. Holdsworth et al.
37. Darke C, Street J, Hammond L, Downing J, Thompson J. 50. Przemeck M, Elsner H-A, Sel S, Pastucha LT, Blasczyk R.
Immunogenetic study of a new HLA allele B*2723. Tissue HLA-B*4431: a new HLA-B variant with a complex ancestral
Antigens 2002: 60: 400–3. history involving HLA-B*44, B*40 and B*07 alleles. Tissue
38. Elsner H-A, Himmel A, Steitz M et al. HLA-B*3531, a hybrid Antigens 2002: 60: 91–4.
of B35 and B61, implications for diagnostic approaches to 51. Poli F, Longhi E, Frison S et al. Identification of a novel
alleles with complex ancestral compositions. Tissue Antigens HLA-B allele – HLA-B*4902. Tissue Antigens 2001: 57: 173–4.
2002: 60: 95–7. 52. Darke C, Street J, Guttridge MG. Sequence, genetics and
39. Swelsen WTN, Voorter CEM, van den Berg-Loonen EM. serology of a new HLA-B allele: B*4903. Tissue Antigens 2001:
Sequence analysis of exons 1, 2, 3, 4 and 5 of the 57: 478–80.
HLA-B5/35 cross-reacting group. Tissue Antigens 2002: 53. Voorter CEM, Hepkema BG, Mulkers EMT, Lems SPM, van
60: 224–34. den Berg-Loonen EM. Identification of two new HLA-B22
40. Estefania E, Gomez-Lozano N, de Pablo R, Moreno ME, variants, HLA-B*5509 and B*5606. Tissue Antigens 2001:
Vilches C. Complementary DNA sequence of the novel 58: 42–6.
HLA-B*3704 allele. Tissue Antigens 2002: 59: 142–4. 54. Park H-S, Choi J-H, Lee KW. Identification of a novel
41. Pyo C-W, Han H, Kim T-G. Identification of a new HLA-B HLA-B*55 variant (B*5513) from a Korean family. Tissue
allele, B*3705, containing a Bw6 sequence motif. Tissue Antigens 2004: 64: 96–8.
Antigens 2002: 59: 335–7. 55. Lyou J-Y, Yang KL, Lee A, Lin PY, Lee TD. Confirmation of
42. Garcia-Sanchez F, Fernandez-de-Velasco J, Lillo R et al. a recombinant allele B*5603 and a hypothetical reciprocal
Two new HLA class I alleles recognised by PCR-SSP hybrid. Eur J Immunogen 2002: 29: 69–71.
and SBT: B*3805 and Cw*0408. Tissue Antigens 2002: 59: 56. Wu G-G, Cheng L-H, Zhou D et al. Identification of a novel
47–8. allele HLA-B*5610 in a Chinese potential bone marrow donor.
43. Voorter CEM, van den Berg-Loonen EM. Sequence based Tissue Antigens 2003: 61: 256–8.
typing of exons 1-5 of a new HLA-B allele, B*3927. Tissue 57. Poli F, Crespiatico L, Frison S, Longhi E, Marlianici E,
Antigens 2004: 63: 480–3. Scalamogna M. HLA-B*5808, a new HLA-B allele
44. Blanco PV, Theile G, Marcos C, et al. Novel HLA allele, characterized by sequence based typing. Tissue Antigens 2003:
HLA-B*4013, identified from a potential bone marrow 62: 551–3.
recipient. Tissue Antigens 2001: 57: 380–3. 58. Cantwell L, Boyle A, Diviney M et al. Identification of two new
45. Voorter CEM, Hepkema BG, Lems SPM, van den Cw alleles – implication for epitope recognition (ASHI
Berg-Loonen EM. Identification of a new HLA-B*40 variant abstract). Hum Immunol 2002: 63: S37.
B*4035. Tissue Antigens 2003: 61: 89–91. 59. Voorter CEM, Fischer GF, van den Berg-Loonen EM.
46. Peräsaari JP, Koskela S, Partanen J. Characterization a novel Identification of a new HLA-C allele, Cw*0316, by SBT.
HLA-B40 allele with serological Bw4 motif, HLA-B*4047, in Tissue Antigens 2004: 63: 484–6.
the Finnish population and confirmation of B*270503 allele. 60. Testa GV, Bunce M, Sheldon MH, Dunn PPJ, Day S, Marques
Tissue Antigens 2004: 63: 595–7. SBD. Identification of a new allele, HLA-DRB1*1360, on
47. Street J, Downing J, Darke C. Immunogenetics of the a DRB5 haplotype in a Brazilian individual. Tissue Antigens
rare HLA-B allele B*4408. Eur J Immunogen 2003: 2004: 63: 617–8.
30: 129–31. 61. Hammond L, Bengtsson M, Street J et al. HLA-A*2312-a
48. Darke C, Street J, Downing J. Immunogenetics of two new novel allele found in testing for the UK NEQAS H & I DNA
HLA-B alleles: B*4414 and B*5708. Tissue Antigens 2003: HLA typing scheme. Tissue Antigens 2006: 68: 175–6.
62: 436–41. 62. Dubois V, Tiercy JM, Labonne MP, Dormay A, Gebuhrer L.
49. Canossi A, Papola F, Liberatore G et al. Identification of the A new HLA-B44 allele (B*4402012S) with a splicing mutation
novel allele B*4427 and a confirmatory sequence (B*44022). leading to a complete deletion of exon 5. Tissue Antigens 2004:
Tissue Antigens 2002: 59: 331–4. 63: 173–80.
170 ª 2009 John Wiley & Sons A/S Tissue Antigens 73, 95–170